fsa 28 feb 2003 - landlaeknir.is · sykursýki af tegund tvö 832 lÆknablaÐiÐ2002/88...
TRANSCRIPT
empty Sigurethur HelgasonRitstjoacuteri Kliacuteniacuteskraleiethbeininga
Kliacuteniacuteskar leiethbeiningar
Forsiacuteetha Gaeligethi ogeftirlit
Stofnanir og starfsfoacutelk iacuteheilbrigethisthornjoacutenustu
Lyacuteethheilsa Soacutettvarnir Heilbrigethistoumllfraeligethi Kvartanir og
kaeligrur
Kliacuteniacuteskar leiethbeiningar
Landlaeligknisembaeligttieth
Uacutetgaacutefa
Skraacutening iacuteheilbrigethisthornjoacutenustu
Kliacuteniacuteskar leiethbeiningar
--Bakverkir--Barnaastmi--Beinthornynning af
voumlldum sykurstera--Endurliacutefgun - nyacutett--Hjarta- og
aeligethasjuacutekdoacutemar--Huacuteethfluacuterhuacuteethgoumltun--Houmlfuethaacuteverkar--Klamyacutediacutea--Langvinn lungnateppa
- nyacutett--Lifrarboacutelga C--MS--Neyethargetnaetharvoumlrn--Ofnaeligmislost--Ristilkrabbamein--Sykursyacuteki af tegund 2--Um kliacuteniacuteskar
leiethbeiningar--Aethrir vefir--Fraeligethslufundir--Leiethbeiningar iacute
vinnslu
Loumlg og reglugerethir
Eyethubloumleth
Aethrir vefir
English
Kliacuteniacuteskar leiethbeiningar
Kliacuteniskar leiethbeiningar
SkilgreiningKliacuteniacuteskar leiethbeiningar (clinical guidelines) eru kerfisbundnar leiethbeiningar (ekki fyrirmaeligli) um aacutekvarethanir sem luacuteta aethkliacuteniacuteskum vandamaacutelum iacute laeligknisfraeligethi THORNaeligr taka mieth af bestu thornekkingu aacute hverjum tiacutema og eru lagethar fram iacute thornviacute skyni aethveita sem besta meethfereth meeth sem minnstri aacutehaeligttu aacuten oacutehoacuteflegs kostnaethar meira
Erlendar stofnanir semgefa uacutet kliacuteniacuteskar
leiethbeiningar
Scottish IntercollegiateGuideline Network
NICE
New Zealand GuidelinesGroup
Naacutenar um gereth kliacuteniskra leiethbeininga
Styacuterihoacutepur Stuethningsaethilar
Vinnuhoacutepar Vinnulag vieth gereth kliacuteniacuteskar leiethbeininga
Stigun raacuteethlegginga
Kliacuteniacuteskar leiethbeiningarsem nuacute eru iacute vinnslu
Influacuteensa - lyfjameethfereth
Offita barna Greining og meethfereth
Eyrnaboacutelga Greining og meethfereth
Uppfaeligrt 25 apriacutel 2003
Sjaacute einnig Stuethningsaethilar Prentvaelign uacutetgaacutefa
Landlaeligknisembaeligttieth Austurstroumlnd 5 170 Seltjarnarnes siacutemi 510 1900 fax 510 1919 toumllvupoacutestur posturlandlaekniris
Forsiacuteetha Gaeligethi ogeftirlit
Stofnanir og starfsfoacutelk iacuteheilbrigethisthornjoacutenustu
Lyacuteethheilsa Soacutettvarnir Heilbrigethistoumllfraeligethi Kvartanir og
kaeligrur
Kliacuteniacuteskar leiethbeiningar Um kliacuteniacuteskar leiethbeiningar Vinnuhoacutepar
Vinnuhoacutepar
Vinnuhoacutepar vieth gereth kliacuteniacuteskra leiethbeininga
Aacutehaeligttumat kransaeligethasjuacutekdoacutema (Leiethbeiningar uacutetgefnar 2001)Gunnar Toacutemasson laeligknirSigurethur Helgason laeligknir Bakverkur (Leiethbeiningar uacutetgefnar iacute desember 2002)Magnuacutes Oacutelason laeligknirGiacutesli THORN Juacuteliacuteusson laeligknirRagnar Joacutensson laeligknirSigurethur Helgason laeligknir Barnaastmi (Leiethbeiningar uacutetgefnar iacute maiacute 2002)Bjoumlrn Aacuterdal laeligknirGunnar Joacutenasson laeligknirIngoacutelfur Kristjaacutensson laeligknirRannveig Einarsdoacutettir lyfjafraeligethingurSigurethur Helgason laeligknir (formaethur)Sigurethur Kristjaacutensson laeligknir Beinthornynning (iacute vinnslu)Aethalsteinn Guethmundsson laeligknir (formaethur)Ari Joacutehannesson laeligknirBjoumlrn Guethbjoumlrnsson laeligknirRannveig Einarsdoacutettir lyfjafraeligethingurSigriacuteethur Bjoumlrnsdoacutettir laeligknirSigurethur Helgason laeligknir Beinthornynning af voumlldum sykurstera (Leiethbeiningar uacutetgefnar iacute februacutear 2002)Aethalsteinn Guethmundsson laeligknirBjoumlrn Guethbjoumlrnsson laeligknir (formaethur)Rannveig Einarsdoacutettir lyfjafraeligethingurSigurethur Helgason laeligknir Braacuteethir kransaeligethasjuacutekdoacutemar (Leiethbeiningar uacutetgefnar iacute mars 2002)Daviacuteeth O Arnar laeligknirRagnar Daniacuteelssen laeligknir
Braacuteethur niethurgangur hjaacute boumlrnum (iacute vinnslu)Luacutether Sigurethsson laeligknirUacutelfur Agnarsson laeligknir
BuprenorphineErla Axelsdoacutettir laeligknirGuethbjoumlrn Bjoumlrnsson laeligknirMatthiacuteas Halldoacutersson laeligknirTHORNoacuterarinn Tyrfingsson laeligknirTHORNoacuterethur G Oacutelafsson laeligknir
Endurliacutefgun seacuterhaeligfeth (Leiethbeiningar uacutetgefnar iacute mars 2003)Daviacuteeth O Arnar laeligknirHjalti Maacuter Bjoumlrnsson laeligknir
Faglegir umsagnaraethilarAri Joacutehannesson laeligknirFelix Valsson laeligknirHrafnkell Oacuteskarsson laeligknirLaacuterus Petersen Landssambandi Sloumlkkvilieths og sjuacutekraflutningamannaRagnar Danielsen laeligknirTHORNoacuterir B Kolbeinsson laeligknir
--Hjarta- ogaeligethasjuacutekdoacutemar
--Huacuteethfluacuterhuacuteethgoumltun--Houmlfuethaacuteverkar--Klamyacutediacutea--Langvinn lungnateppa
- nyacutett--Lifrarboacutelga C--MS--Neyethargetnaetharvoumlrn--Ofnaeligmislost--Ristilkrabbamein--Sykursyacuteki af tegund 2--Um kliacuteniacuteskar
leiethbeiningar--- Vinnuhoacutepar--- Vinnulag--- Stigun raacuteethlegginga--- Stuethningsaethilar--- Styacuterihoacutepur
--Aethrir vefir--Fraeligethslufundir--Leiethbeiningar iacute
vinnslu
Loumlg og reglugerethir
Eyethubloumleth
Aethrir vefir
English
Rannveig Einarsdoacutettir lyfjafraeligethingurSigurethur Helgason laeligknir Hoacutepur stofnaethur iacute oktoacuteber 2002Huacuteethfluacuterun og goumltun (Leiethbeiningar uacutetgefnar iacute september 2000)Aacuternyacute Sigurethardoacutettir hjuacutekrunarfraeligethingurAacutesa Atladoacutettir hjuacutekrunarfraeligethingurMatthiacuteas Halldoacutersson laeligknirSigurethur Helgason laeligknir (formaethur)
Houmlfuethaacuteverkar (Leiethbeiningar uacutetgefnar iacute noacutevember 2001)Kristinn R Guethmundsson laeligknir (formaethur)Bjarni Hannesson laeligknirGunnar Toacutemasson laeligknirSigurethur Helgason laeligknirTHORNorbergur Houmlgnason laeligknir
Influacuteensa (iacute vinnslu)Gunnar Gunnarsson laeligknirGunnar Toacutemasson laeligknirMagnuacutes Gottfreethsson laeligknir (formaethur)
Kinnholuboacutelga hjaacute boumlrnum (iacute vinnslu)Friethrik Guethbrandsson laeligknirKarl G Kristinsson laeligknirVilhjaacutelmur A Arason laeligknir (formaethur)THORNoacuteroacutelfur Guethnason laeligknir
Klamyacutediacutea ( Leiethbeiningar uacutetgefnar iacute februacutear 2001)Joacuten Hjaltaliacuten Oacutelafsson laeligknirOacutelafur Steingriacutemsson laeligknirRannveig Einarsdoacutettir lyfjafraeligethingurReynir Toacutemas Geirsson laeligknirSigurethur Helgason laeligknirSteingriacutemur Daviacuteethsson laeligknir (formaethur)
Langvinnir lungnateppusjuacutekdoacutemar (Leiethbeiningar uacutetgefnar iacute mars 2003)Gunnar Guethmundsson laeligknirHalldoacuter Joacutensson laeligknirJoacuten Bjarnarson laeligknirSigurethur Helgason laeligknirTHORNoacuterarinn Giacuteslason laeligknir (formaethur)
Mjaethmarbrot forvarnir og meethfereth (iacute vinnslu)Aethalsteinn Guethmundsson laeligknirFriethrik V Guethjoacutensson laeligknirHalldoacuter Joacutensson laeligknirJoacuten Ingvar Ragnarsson laeligknirOacuteloumlf R Aacutemundadoacutettir sjuacutekrathornjaacutelfiSigurethur Helgason laeligknirYngvi Oacutelafsson laeligknirTHORNorvaldur Ingvarsson laeligknir (formaethur)
Faglegir raacuteethgjafarGirish HirlekarOacutelafur R IngimarssonPaacutell Torfi OumlnundarsonPeacutetur HannessonSigurethur B THORNorsteinsson
Myndgreining (Leiethbeiningar uacutetgefnar iacute september 2000)Aacutesmundur Brekkan laeligknir (formaethur)Baldur F Sigfuacutesson laeligknirEythornoacuter Bjoumlrgvinsson laeligknirHalldoacuter Benediktsson laeligknirHaukur Valdimarsson laeligknirKolbruacuten Benediktsdoacutettir laeligknirOacutelafur Kjartansson laeligknirSigurethur Helgason laeligknir
Endurskoethun iacute mars 2003Anna Bjoumlrg Halldoacutersdoacutettir roumlntgenlaeligknirGuethlaugur Einarsson geislafraeligethingurGuethmundur Joacuten Eliacuteasson roumlntgenlaeligknirHalldoacuter Benediktsson roumlntgenlaeligknirIethunn Leifsdoacutettir roumlntgenlaeligknirJoumlrgen Albrechtsen roumlntgenlaeligknirKolbruacuten Benediktsdoacutettir roumlntgenlaeligknir (formaethur)Kristbjoumlrn Reynisson roumlntgenlaeligknirPeacutetur Hannesson roumlntgenlaeligknir
Neyethargetnaetharvoumlrn (Leiethbeiningar uacutetgefnar iacute mars 2001 endursk noacutevember 2002 og mars 2003)Anna Bjoumlrg Aradoacutettir hjuacutekrunarfraeligethingurHjoumlrdiacutes Harethardoacutettir laeligknir
LaeligknablaethiethHliacuteethasmaacutera 8 - 201 KoacutepavogiSiacutemi 564 4104 - Fax 564 4106
2 tbl 88 aacuterg 2002
Houmlfundar
AethalsteinnGuethmundsson12Sigurethur Helgason23Bjoumlrn Guethbjoumlrnsson4
Yfirlit
InngangurEnglish SummaryMeingerethSkilgreiningarMeethferethBisfosfoacutenoumltOumlstroacutegenRaloxifen og tiacuteboacuteloacutenTestoacutesteroacutenKalsiacutetoacuteniacutenTiacuteaziacuteeth thornvagraeligsilyfNyacutejar meethferetharleiethirSamantektHeimildir
Lykiloreth
sykursterar beinthorneacutettnibeinthornynningbisfosfoacutenoumlt D-viacutetamiacutenkalk karlhormoacutenkvenhormoacuten
Almennt
1Oumlldrunarsvieth2Landspiacutetali - Hrafnistu3Landlaeligknisembaeligttieth4Rannsoacuteknarstofa iacutegigtsjuacutekdoacutemumFyrirspurnir BjoumlrnGuethbjoumlrnsson netfangbjorngulandspitaliisGrein thornessi er afraksturstarfshoacuteps um kliacuteniacuteskarleiethbeiningar aacute vegum
Fraeligethigreinar
Forvarnir og meethferethbeinthornynningar af voumlldumsykurstera KliacuteniacuteskarleiethbeiningarBeinthornynning er algeng og alvarleg hjaacuteverkun langtiacutemameethferethar meethsykursterum Meeth virkri forvoumlrn ogeetha seacutertaeligkri meethfereth gegnbeinthornynningu er unnt aeth draga uacuter thorneim heilsufarsvanda ogsamfeacutelagskostnaethi sem hlyacutest af beinthornynningu af voumlldumsykursterameethferethar Leiethbeiningar thornessar eru settar fram samkvaeligmt goacuteethriog skynsamlegri aacutekvarethanatoumlku (evidence based) og eru aeligtlaethar laeligknumsem bera aacutebyrgeth aacute meethfereth sjuacuteklinga aacute langtiacutema sykursterameethfereth Iacutedaglegu starfi getur verieth erfitt aeth fylgja thornessum leiethbeiningum til daeligmiseru beinthorneacutettnimaeliglingar eingoumlngu framkvaeligmdar iacute Reykjaviacutek og aacute Akureyri
Inngangur
Sykursterar eru algeng meethfereth vieth moumlrgum boacutelgu- ogbandvefssjuacutekdoacutemum og thorneir eru einnig notaethir til oacutenaeligmisbaeliglingar tildaeligmis eftir liacuteffaeligraiacutegraeligethslur Samkvaeligmt nyacutelegri iacuteslenskri rannsoacutekn maacutegera raacuteeth fyrir thornviacute aeth ruacutemlega 2000 einstaklingar seacuteu aacute samfelldrisykursterameethfereth heacuter aacute landi aacute hverjum tiacutema Helstu aacutebendingar erulangvinnir gigtarsjuacutekdoacutemar (43) lungnasjuacutekdoacutemar (33) eethaboacutelgusjuacutekdoacutemar iacute goumlrn (8) (1)
Sykursterar eru algengasti lyfjaflokkurinn sem orsakar beinthornynningu aethminnsta kosti meethal yngra foacutelks (2) Afleiethingar beinthornynningar aacute heilsufarog liacutefsgaeligethi einstaklinga sem nota sykurstera eru umtalsverethar Fimmtaacutenproacutesent thorneirra sem faacute langtiacutemameethfereth meeth sykursterum veretha fyrirsamfallsbroti iacute hrygg aacute fyrsta meethferetharaacuterinu og thornriethjungur beinbrotnar aacutefyrstu fimm aacuterum meethferethar (3) THORNoacutett ekki seacute aeth fullu ljoacutest hvernigsykursterar valda beinthornynningu er um aeth raeligetha samverkan af haeliggaribeinnyacutemyndun og aukinni beineyethingu meethan aacute meethfereth stendur (4)
Langflestir thorneirra sem nota sykurstera til lengri tiacutema tapa umtalsverethribeinthorneacutettni sem siacuteethan veldur aukinni haeligttu aacute beinbrotum Beintap thornetta erhlutfallslega hraethast fyrstu meethferetharmaacutenuethina Faraldsfraeligethilegarrannsoacuteknir hafa syacutent aeth haeligtta aacute beinbrotum thornaacute seacuterstaklega iacute hrygg ogmjoumlethm eykst iacute reacutettu hlutfalli vieth skammtastaeligreth og tiacutemalengdmeethferetharinnar (5)
Kannanir heacuterlendis og erlendis hafa syacutent aeth mjoumlg stoacuter hluti thorneirra sjuacuteklingasem nota sykurstera faeligr oacutefullnaeliggjandi forvoumlrn gegn beinthornynningu (1 6-8)THORNessar rannsoacuteknir syacutena aeth einstaklingar sem hafa thornekkta beinthornynningu(jafnvel meeth beinbrotum) iacute upphafi sykursterameethferethar njoacuteta ekki thorneirrarmeethferethar sem voumll er aacute iacute dag Aacute undanfoumlrnum aacuterum hafa opnast nyacuteirmoumlguleikar til greiningar beinthornynningu og ekki siacuteethur varethandi forvoumlrn og
Tafla I
Tafla II
Tafla III
Tafla IV
Tafla V
Sykursyacuteki af tegund tvouml
832 LAElig K NAB LAETHI ETH 200288
Taeligkifaeligrisskimun aacutehaeligttuhoacutepa aacute eins til thornriggja aacutera fresti
Iacute aacutehaeligttuhoacutepi eru thorneir sem
hafa haacutethornryacutesting hjarta- eetha aeligethasjuacutekdoacutem eru ekki af evroacutepskum uppruna
eru of feitir eru 20 eetha meira yfir kjoumlrthornyngd hafa skert sykurthornol (IGT ndash impaired glucose= thornyngdarstuethull (BMI ndash body mass index) ge27 tolerance) eetha haeligkkaethan foumlstu bloacuteethsykur
(IFG ndash impaired fasting glucose) hafa haeligkkaethar bloacuteethfitur seacuterstaklega TG
og laacutegt HDL hafa fengieth sykursyacuteki aacute meethgoumlngu
eiga foreldra eetha systkin meeth sykursyacuteki eru 45 aacutera eetha eldri
TG triglyceridethornriacuteglyacuteseriacuteeth HDL high densityhaacutethorneacutettni liacutepoacuteproacutetiacuten
Taeligkifaeligrisskimun meeth fastandi sykri iacute heilbloacuteethi (iacute sermi)
Ekki sykursyacuteki lt 56 (65) ge 56 (65)
Endurtaka
lt 56 (61) 56-60 (61-69) 2 gildi ge 61 (70)
Sykursyacuteki
Haeligkkaethur foumlstu bloacuteethsykur (hugleietha sykurthornolsproacutef)
Meethhoumlndlunarmarkmieth og tiacuteethni eftirlits
Maeliglistaeligreth Tiacuteethni Viethmiethunarmoumlrk
HbA1c Aacute thornriggja til toacutelf maacutenaetha fresti lt 70
Liacutekamsthornyngd Vieth hverja komu til laeligknis
Liacutekamsthornyngdarstuethull BMI Einstaklingsbundieth(Karlar 20-25)(Konur 19-24)
Bloacuteeththornryacutestingur Vieth hverja komu til laeligknis lt 14080
Heildarkoacutelesteroacutel Aacuterlega lt 50 mmoacutellHDL-koacutelesteroacutel Aacuterlega gt 12 mmoacutellLDL-koacutelesteroacutel Aacuterlega lt 30 mmoacutellTHORNriacuteglyacuteseriacuteeth Aacuterlega lt 17 mmoacutell
Sykraethur bloacuteethrauethi HDL high densityhaacutethorneacutettni liacutepoacuteproacutetiacuten LDL low densitylaacutegthorneacutettni liacutepoacuteproacutetiacuten
Starfshoacutepur aacute vegum Land-
laeligknisembaeligttis hefur unnieth
aeth gereth kliacuteniacuteskra leiethbeininga
um greiningu og meethfereth
sykursyacuteki af tegund tvouml Iacute
hoacutepnum eru Aacutestraacuteethur B
Hreietharsson Houmlrethur Bjoumlrns-
son (formaethur) Rafn Bene-
diktsson Ragnar Gunnarsson
Rannveig Einarsdoacutettir og
Oacutefeigur THORNorgeirsson
Hoacutepurinn lauk vinnu iacute juacuteniacute
2002 og thornaacute birtust leiethbein-
ingarnar aacute vef Landlaeligknis
Vieth vinnuna var einkum
stuethst vieth nyacutelegar nyacutesjaacutelensk-
ar leiethbeiningar um efnieth thornar
sem thornaeligr thornoacutettu aethgengi-
legastar og byggethar aacute
gagnreyndri laeligknisfraeligethi eins
og sjaacute maacute aacute sloacuteethinni
wwwnzggorgnz
librarycfm
F R AElig ETH I G R E I N A R K L Iacute N Iacute S K A R L E I ETH B E I N I N G A R F R Aacute L A N D L AElig K N I S E M B AElig T T I N U
Sykursyacuteki af tegund tvouml
Toumllur iacute sviga eiga vieth maeliglingar iacute sermi
Kliacuteniacuteskar leiethbeiningar um myndgreiningu
Iacuteslenskar leiethbeiningar um myndgreiningu hafa verieth gefnar uacutet og eru nuacute aethgengilegar aacuteupplyacutesingavef LSH THORNaeligr eru einkum byggethar aacute breskum leiethbeiningum sem voru gefnar uacutet 1998 afUK Royal College of Radiologists og evroacutepskum leiethbeiningum fraacute aacuterinu 2000 EuropeanCommission Referral Guidelines for Imaging en thornaeligr byggja aacute grunni hinna breskuEvroacutepuleiethbeiningarnar hafa verieth thornyacuteddar aacute fjoumllmoumlrg tungumaacutel thorn aacute m finnsku doumlnsku og saelignskuVoru thornaeligr hafethar aeth leietharljoacutesi vieth gereth iacuteslensku leiethbeininganna en innihald thorneirra thornoacute lagaeth aethiacuteslenskum aethstaeligethum
Markmieth leiethbeininganna er aeth leiethbeina um val aacute rannsoacuteknum og veita upplyacutesingar umgeislaskammta og kostnaeth vieth myndgreiningarannsoacuteknir iacute von um aeth hvort tveggja skili seacuter iacutemarkvissri notkun myndgreiningarthornjoacutenustu
Leiethbeiningarnar eru birtar vieth houmlndina aacute heimasiacuteethu myndgreiningarthornjoacutenustu aacute upplyacutesingavef LSHog undir Nyacuteir vefir aacute forsiacuteethu vefsins
Leiethbeiningarnar eru unnar iacute samvinnu Landspiacutetala - haacuteskoacutelasjuacutekrahuacutessLandlaeligknisembaeligttisins og Feacutelags iacuteslenskra roumlntgenlaeligkna
Landlaeligknisembaeligttieth Landspiacutetali - haacuteskoacutelasjuacutekrahuacutes Feacutelag iacuteslenskra roumlntgenlaeligkna
Vinnuferlar um seacuter-haeligfetha endurliacutefgun erubyggethir aacute althornjoacuteethlegumleiethbeiningum iacute endur-liacutefgun sem gefnar voru
uacutet aacuterieth 2000 (Inter-national Guidelines2000 on Cardiopul-
monary Resuscitationand Emergency
Cardiovascular Care)Ferlarnir voru thornyacuteddir ogstaethfaeligrethir af Hjalta MaacuteBjoumlrnssyni og Daviacuteeth O
Arnar og hafa veriethstaethfestir af
EndurliacutefgunarraacuteethiFeacutelagi slysa- og braacuteetha-
laeligkna Feacutelagi hjarta-laeligkna Feacutelagi heimilis-laeligkna og Feacutelagi svaeligf-
ingar- og gjoumlrgaeligslu-laeligkna
128 LAElig K N AB LAETHI ETH 200389
F R AElig ETH I G R E I N A R K L Iacute N Iacute S K A R L E I ETH B E I N I N G A R F R Aacute L A N D L AElig K N I S E M B AElig T T I N U
Vinnuferlar fyrir endurliacutefgunVinnuferlar fyrir endurliacutefgun
Fyrra ABCDAacutehersla Aeth veita grunnendurliacutefgun og gefa rafstueth
bull Staethfesta meethvitundarleysibull Raeligsa neyetharteymibull Saeligkja rafstuethtaeligkiOpna (Airway) Opna oumlndunarveg lyfta undir houmlkuBlaacutesa (Breathing) Blaacutesa lofti iacute sjuacutekling meeth maska og belg eetha blaacutestursgriacutemuHnoetha (Circulation) Hefja hjartahnoeth nema merki um bloacuteethflaeligethi seacuteu til staetharStuetha (Defibrillation) Meta takt og stuetha VFpuacutelslausan VT allt aeth thornrisvar iacute roumleth ef thornarf
(Einfasa stuethtaeligki 200 J 300 J 360 J Tviacutefasa stuethtaeligki 150 J 200 J 200 J)
Taktur eftir fyrstu thornrjuacute stueth
Viethvarandi eethaendurtekieth VFVT
Athuga liacutefsmoumlrkFrekari lyfjameethferethDraga bloacuteethprufur
(K+ Ca2 Mg2+ hjartaensiacutem)Hjartaliacutenurit
Seinna ABCDAacutehersla Naacutekvaeligmari greining og meethfereth
(Minnisregla ndash thornarf ekki aeth framkvaeligma iacute thornessari roumleth)
Airway Barkathornraeligetha eins fljoacutett og haeliggt er og setja loft iacute belgBreathing Staethfesta legu aacute barkarennu meeth skoethun og taeligkiBreathing Tryggja barkarennu helst meeth seacutertilgerethri festinguBreathing Staethfesta suacuterefnismettun og loftskiptiCirculation IV naacutel (aeligethaleggur)Circulation Greina takt ndash hjartarafsjaacuteCirculation Gefa lyf iacute samraeligmi vieth takt og aacutestand sjuacuteklingsDifferential diagnosis Mismunagreiningar leita aeth undirliggjandi orsoumlk og meethhoumlndla ef haeliggt er
Adrenaliacuten 1 mg IV gusa endurtekin aacute thornriggja til fimm miacutenuacutetna frestieetha
Vasoacutepressiacuten 40 U IV gusa (tvaeligr lykjur) Einn skammtur einu sinni
Stuetha ef takttruflun er enn til staethar1 x 360 J (eetha tviacutefasa 200 J) innan 30-60 sekuacutendna
Reyna aftur aeth stuetha ef takttruflun er enn til staethar30-60 sekuacutendum eftir hverja lyfjagjoumlf
Iacutehuga hjartslaacutettartruflanalyfAmiacuteoacutedaroacuten 300 mg IV Liacutedoacutekaiacuten 075 mgkg IV
Magnesiacuteum 1-2 g IV aacute tveimur miacutenuacutetum Iacutehuga basagjoumlf
Sleglatif og sleglahraethtaktur aacuten merkja um bloacuteethflaeligethi(VF1puacutelslaus VT2)
Jaacute
Nei
1 VF = Ventricular Fibrillation2 VT = Ventricular Tachycardia
Nota Vasoacutepressiacuten frekar efhjartastopp er talieth af voumlld-um bloacuteeththornurrethar iacute hjarta Ef
Vasoacutepressiacuten er notaeth maacutegefa Adrenaliacuten 1 mg aacute
thornriggja til fimm miacutenuacutetnafresti 10-15 miacutenuacutetum siacuteethar
Amiacuteoacutedaroacuten maacute gefa 300 mgiacute gusu Siacuteethan maacute endurtaka
150 mg gusur ef enn VFpuacutelslaus VT haacutemarks-
skammtur 24 g aacute 24klukkustundum
Gefa Magnesiacuteum ef thornekkthypomagnesemiacutea eetha
hraethtaktur meeth gleiethumQRS-bylgjum
Biacutekarboacutenat maacute gefa efum er aeth raeligetha thornekkta
hyperkalemiacuteu efnaskipta-syacuteringu eetha eitrun af voumlld-
um thornriacutehringlaga geeth-deyfetharlyfja
Unnur Steina BjoumlrnsdoacutettirSigurveig THORN Sigurethardoacutett-ir og Bjoumlrn Ruacutenar Luacuteethviacuteks-son skipuethu vinnuhoacutep um
leiethbeiningar um ofnaeligmis-lost THORNaeligr hafa verieth unnar
iacute samvinnu vieth SigurethHelgason ritstjoacutera kliacuten-
iacuteskra leiethbeininga ogRannveigu Einarsdoacutettur
yfirlyfjafraeligething LSH Leieth-beiningarnar hafa verieth
samthornykktar af Feacutelagi iacutes-lenskra ofnaeligmis- og
oacutenaeligmislaeligkna og verethaendurskoethaethar iacute ljoacutesi
nyacuterrar vitneskju en eigisiacuteethar en eftir tvouml aacuter
920 LAElig K NAB LAETHI ETH 200288
F R AElig ETH I G R E I N A R K L Iacute N Iacute S K A R L E I ETH B E I N I N G A R F R Aacute L A N D L AElig K N I S E M B AElig T T I N U
Grunur um ofnaeligmislostUrticaria (ofsaklaacuteethi)
Angioedema (ofsabjuacutegur)Hvaeligsandi oumlndun
Liacutefshaeligttuleg einkenniPuacutels BloacuteeththornryacutestingurMerki um suacuterefnisskort
MismunagreiningarOacutevenjuleg sjuacutekdoacutemsmynd
Endurmat
MeethferetharmoumlguleikarAdrenaliacuten IMAntihistamiacutenBarksterar
Fjarlaeliggja ofnaeligmisvald
Kalla eftir aethstoeth (112 neyetharhnappur)Adrenaliacuten Fullorethnir 03-05 mg IM (11000 03-05 ml)
Boumlrn 001 mgkg IM (haacutemark 03-05 mg)Antihistamiacuten Fullorethnir Diacutefenhyacutedramiacuten 50-75 mg IV aacute 5-10 miacutenuacutetum IM eetha PO
Boumlrn 1 mgkg IV eetha PO (haacutemark 75 mg)Fjarlaeliggja ofnaeligmisvald
Ef sjuacuteklingur svarar ekki meethfereth skal hefjaENDURLIacuteFGUN O2 iacute nefgriacutemu halda suacuterefnismettun iacute bloacuteethi gt 90
Hroumleth voumlkvun (09 NaCl Ringerslausn eetha kvoethulausn)BarksterarBloacuteeththornryacutestingshaeligkkandi innrennslislyf (Vasopressors)Berkjuviacutekkandi innoumlndunarlyf
Fullorethnir Ventoliacuten 2 mgml 25 ml gefnir iacute frietharpiacutepu meeth O2
Boumlrn Ventoliacuten 01 mgkg gefnir iacute frietharpiacutepu meeth O2 (haacutemark 5 mg)
BarkathornraeligethingBarkaaacutestunga (varhugavereth lt 10 aacutera)
EndurmatNaacutekvaeligm saga ndash orsakaleit (lyf faeligetha umhverfi athafnir)Voumlktun eftir ofnaeligmislost
Vaeligg ndash miethlungs (ofsaklaacuteethi berkjukrampi) 12 klukkustundirAlvarleg (breyting aacute liacutefsmoumlrkum viethvarandi berkjukrampi) gt 24 klukkustundir
Kennsla ndash raacuteethleggingarEpiPen sprautaMedic Alert merki
NEI
NEI
JAacute
JAacute
IV ndash intravenous = iacute aeligeth IM ndash intramuscular = iacute voumlethva PO ndash per os = um munn
Ofnaeligmislost (anaphylaxis)Ofnaeligmislost (anaphylaxis)
Meethfereth ndash flaeligethirit
Ef grunur er um ofnaeligmislost aacute aeth gefa adrenaliacuten iacute voumlethva (03 til 05 mg eetha 03 til 05 ml af 11000 lausn) og fjarlaeliggja ofnaeligmisvald strax
LAElig K NAB LAETHI ETH 200288 921
F R AElig ETH I G R E I N A R K L Iacute N Iacute S K A R L E I ETH B E I N I N G A R F R Aacute L A N D L AElig K N I S E M B AElig T T I N U
IV ndash intravenous = iacute aeligeth IM ndash intramuscular = iacute voumlethva PO ndash per os = um munn
Ofnaeligmislost (anaphylaxis)Ofnaeligmislost (anaphylaxis)
Ofnaeligmislost ndash Notkun og skammtastaeligrethir lyfja
FullorethnirI Adrenaliacuten 03-05 mg Ef gefieth er iacute voumlethva thornaacute skal nota iacute thornynningunni 11000 en 110000 thornynnt iacute 5
ml af 09 NaCl ef gefieth er IV eetha iacute barkasloumlngu Endurtaka aacute 10-15 miacutenuacutetna fresti thornar til svoumlrunnaeligst Reacutett er aeth byrja meeth laeliggri skammta hjaacute oumlldruethum eetha hjartasjuacuteklingum (02-04 mg)
II AntihistamiacutenA H1-hemjarar
ndash Difenhyacutedramiacuten 25-75 mg IV aacute 5-10 miacutenuacutetum IM eetha PO maacute endurtaka aacute sex klukkustunda fresti
ndash Clemastinum (Tavegylreg) 1-3 mg PO maacute endurtaka aacute 12 klukkustunda fresti
B H2-hemjararndash Ranitidin 300 mg PO aacute soacutelarhring eetha 50 mg IV aacute aacutetta klukkustunda frestindash Cimetidine 300 mg PO
III BarksterarA Prednisoacuteloacuten 05-1 mgkgsoacutelarhring iacute tveimur til thornremur joumlfnum skoumlmmtum PO
B Metyacutelprednisoacuteloacuten (Solu-Medrolreg) 1-2 mgkgsoacutelarhring iacute tveimur joumlfnum skoumlmmtum IV
C Hyacutedroacutekortiacutesoacuten (Solu-Cortefreg) 150-200 mg IV aacute sex til aacutetta klukkustunda fresti (5-10 mgkg)Minnka skammt niethur iacute ekkert aacute tveimur til fjoacuterum doumlgum eftir einkennum
IV Bloacuteeththornryacutestingshaeligkkandi innrennslislyf ndash VasopressorsA EfedriacutenAdrenaliacutenNorepinephrine 2-12 gmiacuten
B Doacutepamiacuten 2-20 gkgmiacuten
V Ef sjuacuteklingur er aacute -hemjandi meethferethA Gluacutekagon 1-5 mg IV gefieth aacute tveimur til fimm miacutenuacutetum
B Isoacuteproacuteterenoacutel Upphafsskammtur er 2 gmiacuten tiacutetreraeth thornar til aeth hjartslaacutettur er 60 sloumlg aacute miacutenuacutetuogeetha eethlilegum bloacuteeththornryacutestingi hefur verieth naacuteeth
BoumlrnI Adrenaliacuten
11000 001 mgkg IM (= 001 mlkg IM) eetha adrenaliacuten 110000 001 mgkg (=01 mlkg) IV(mest 03-05 mg) THORNennan skammt maacute endurtaka aacute 15 miacutenuacutetna fresti tvisvar sinnum
II AntihistamiacutenA H1-hemjarar
ndash Difenhyacutedramiacuten 1 mgkg IV IM eetha PO aacute sex klukkustunda fresti iacute aeth minnsta kosti 48 klukku-stundir mest 75 mgskammt
ndash Clemastinum INN (Tavegylreg) 002-006 mgkg skammt eetha 3-6 aacutera 05 mg PO 6-12 aacutera 05-1 mg PO maacute endurtaka aacute 12 klukkustunda fresti
B H2-hemjararndash Ranitidin 1 mgkgskammt IV 2-3 mgkgskammt PO (mest 300 mg) endurtaka eftir 12
klukkustundir ndash Cimetidine 10 mgkgskammt (mest 300 mg) IV eetha PO endurtaka eftir aacutetta klukkustundir
III BarksterarPrednisoacuteloacuten 05-1 mgkg PO iacute tveimur til thornremur joumlfnum skoumlmmtum Solumedrol 1 mgkg IV gefieth aacute30 miacutenuacutetum (skammtur fyrir boumlrn raeligethst af sjuacutekdoacutemsaacutestandi fremur en aldri og staeligreth) maacute endurtakaaacute aacutetta klukkustunda fresti iacute 48 klukkustundir
THORNungaethar konurOumlruggt er talieth aeth nota adrenaliacuten diacutefenhyacutedramiacuten og barkstera THORNoacute er raacuteethlegt aeth gefa efedriacuten 10-15mg IV ( gtgt adreniacutesk aacutehrif hefur minni aacutehrif aacute samdraacutett legs en adrenaliacuten) ef ekki er um liacutefshaeligttu-leg einkenni aeth raeligetha
LaeligknablaethiethHliacuteethasmaacutera 8 - 201 KoacutepavogiSiacutemi 564 4104 - Fax 564 4106
3 tbl 89 aacuterg 2003
Houmlfundar
Almennt
Umraeligetha amp freacutettir
Leiethbeiningar um lungnateppuEfnt hefur verieth til aacutetaks til aeth vekja athygli raacuteethamannaheilbrigethisstarfsmanna og almennings um allan heim aacute langvinnri lungnateppusem vaxandi heilbrigethisvandamaacuteli Aacutetakieth nefnist Global initiative forchronic Obstructive Lung Disease skammstafaeth GOLD Til thorness aeth baeligtagreiningu og meethfereth sjuacutekdoacutemsins hafa verieth teknar saman althornjoacuteethlegarleiethbeiningar sem voru gefnar uacutet 4 apriacutel 2001 Aeth leiethbeiningunum standameethal annars WHO og NHLBI (National Heart Lung and Blood Institute iacuteBandariacutekjunum) Styacuterihoacutepur um kliacuteniacuteskar leiethbeiningar hefur aacutekveethieth aethkynna thornaeligr og viacutesa til thorneirra aacute vef Landlaeligknisembaeligttisins Af thornessu tilefnihefur seacuterstakur vinnuhoacutepur verieth stofnaethur og iacute honum eru GunnarGuethmundsson lungnalaeligknir Halldoacuter Joacutensson heimilislaeligknir Joacuten Bjarnarsonheimilislaeligknir og THORNoacuterarinn Giacuteslason lungnalaeligknir Leiethbeiningarnar hafa veriethsendar hoacutepi laeligkna til umfjoumlllunar THORNaeligr hafa thornegar verieth samthornykktar af Feacutelagiiacuteslenskra heimilislaeligkna
AEligskilegt er aeth leiethbeiningar thornessar verethi teknar til faglegrar umfjoumlllunar afsem flestum einstaklingum og seacutergreinafeacuteloumlgum Aacutebendingum um breytingarstuddum heimildum maacute koma til formanns vinnuhoacutepsins THORNoacuterarins Giacuteslasonarthorarig landspitaliis
Leiethbeiningarnar maacute einnig naacutelgast aacute heimasiacuteethu GOLD www goldcopdcom
Workshop Report eru lengstar og iacutetarlegastar
Excutive Summary er nokkueth styttri og thornar er haeliggt er skoetha oumlll atriethileiethbeininganna iacute einu pdf-skjali
Pocket Guide er stuttur uacutetdraacutettur uacuter aethalatriethunum AEligtlunin er aeth birta hann aacuteiacuteslensku siacuteethar
Forsiacuteetha Gaeligethi ogeftirlit
Stofnanir og starfsfoacutelk iacuteheilbrigethisthornjoacutenustu
Lyacuteethheilsa Soacutettvarnir Heilbrigethistoumllfraeligethi Kvartanir og kaeligrur
Kliacuteniacuteskar leiethbeiningar Aethrir vefir
Aethrir vefir
Aethrir vefir
meeth kliacuteniacuteskum leiethbeiningum
Tengingar aacute vefi sem annaeth hvort gefa uacutet kliacuteniacuteskar leiethbeiningar eetha dreifa thorneim og gera thornaeligraethgengilegar aacute rafraelignu formi
BandariacutekinAgency for Healhtcare Research and Quality AHRQ aacuteethur AHCPR httpwwwahcprgovclinicNational Guideline ClearinghousehttpwwwguidelinegovSTATICwhatsnewguidelaspview=whatsnewguidelUS Preventive Services Task Force USPSTF og PPIP eetha ldquoPut Prevention Into Practicerdquo httpwwwahcprgovclinicppipixhtmNational Heart Lung and Blood Institute NHLBI httpwwwnhlbinihgovguidelinesindexhtmCenters for Disease Control and Prevention CDC prevention guidelineshttpwondercdcgovwonderprevguidprevguidshtml National Institute of Health NIH Consensus Statements
KanadaCCOHTA httpwwwccohtacaentry_ehtmlBC council on Clinical Practice guidelines httpwwwhlthgovbccamspprotoguidesCanadian Task Force on Preventive health care httpwwwctfphcorgClinical practice guidelines infobase httpmdmcacpgsnewcpgs
Landlaeligknisembaeligttieth - Aethrir vefir
httpwwwlandlaekniristemplate1asppageid=444 (1 of 3) [2122003 225946]
LAElig K NAB LAETHI ETH 200389 61
U M R AElig ETH A amp F R Eacute T T I R F R Aacute L A N D L AElig K N I S E M B AElig T T I N U
Erlendar kliacuteniacuteskar leiethbeiningarErlendar kliacuteniacuteskar leiethbeiningar
Iacute TILEFNI THORNESS aeth nuacute eru taeligp thornrjuacute aacuter fraacute thornviacute vinna viethkliacuteniacuteskar leiethbeiningar hoacutefst aacute vegum Landlaeligknis-embaeligttisins viljum vieth kynna thornaeligr erlendu stofnanirsem vieth teljum skara fram uacuter aacute thornessu sviethi Iacute oumlllum til-vikum standa heilbrigethisyfirvoumlld aeth stofnununum ogmeginmarkmieth thorneirra er aeth baeligta gaeligethi auka skil-virkni (effectiveness) og jafnraeligethi iacute heilbrigethisthornjoacuten-ustu meeth gereth kynningu og hagnyacutetingu (implemen-tation) aacute kliacuteniacuteskum leiethbeiningum sem byggja aacute gagn-reyndri laeligknisfraeligethi (evidence based) Sjuacuteklingumal-menningi og heilbrigethisstarfsfoacutelki eru veittar aacutereieth-anlegar leiethbeiningar um bdquobestu vinnubroumlgethldquo (bestpractice) aacute hverjum tiacutema Iacute sumum tilvikum standastofnanirnar liacuteka aeth thornjaacutelfun heilbrigethisstarfsfoacutelks iacutegereth og kynningu aacute kliacuteniacuteskum leiethbeiningum Von-umst vieth til aeth laeligknar og annaeth heilbrigethisstarfsfoacutelkgeti soacutett gagnlegar upplyacutesingar aacute thornessa staethi thornoacutettlistinn seacute ekki taeligmandi
Statens beredning foumlr medicinsk utvaumlrdering (SBU)var stofnueth 1978 iacute thorneim tilgangi aeth vinna gagnryacutenieth uacuterrannsoacuteknum aacute heilbrigethistaeligkni Mat thorneirra naeligr baeligethitil nyacuterrar taeligkni og taeligkni sem er iacute almennri notkuninnan heilbrigethisgeirans Yfir 50 skyacuterslur hafa veriethbirtar eftir uacutetgaacutefudagsetningu aacute wwwsbuse admin
New Zealand Guideline Group var stofnaeth 1996 meeththornaeth aeth meginmarkmiethi aeth thornjaacutelfa heilbrigethisstarfsfoacutelkiacute gereth og kynningu gagnreyndra kliacuteniacuteskra leiethbein-inga Aacute aacuterunum 1998 til 2002 hafa verieth birtar um 40leiethbeiningar og er thorneim raethaeth iacute efnisroumleth Sjaacute wwwnzggorgnz librarycfm
United States Preventive Services Task Force(USPSTF) iacute Bandariacutekjunum eru thornverfagleg samtoumlksem vinna aeth gereth og uacutetbreiethslu kliacuteniacuteskra leiethbein-inga sem byggja aacute gagnreyndri laeligknisfraeligethi odphposophsdhhsgovpubs
National Health and Medical Research Council(NHMRC) iacute Aacutestraliacuteu eru thornverfagleg samtoumlk semvinna meethal annars aeth gereth og uacutetbreiethslu kliacuteniacuteskraleiethbeininga sem byggja aacute gagnreyndri laeligknisfraeligethiYfir 40 leiethbeiningar hafa verieth birtar eftir uacutetgaacutefu-dagsetningu aacute wwwhealthgovaunhmrcpublications
Canadian Task Force on Preventive Health Care(CTFPHC wwwctfphcorg) sem var stofnaeth 1976hefur thornroacuteaeth mjoumlg faacutegaetha aethferethafraeligethi vieth mat aacute gaeligeth-um rannsoacutekna sem nota aacute vieth gereth kliacuteniacuteskra leiethbein-inga Aethferethafraeligethi thornessi er meethal annars notueth afUnited States Preventive Services Task Force semeinnig hefur naacuteieth samstarf aacute oumlethrum sviethum viethCTFPHC Nuacute er buacuteieth aeth vinna leiethbeiningar um yfir200 heilbrigethistengd efni
The Scottish Intercollegiate Guidelines Network(SIGN) sem var stofnaeth 1993 og myndar thornetta netfjoumlldi laeligkna og annarra heilbrigethisstarfsmanna Oumllllaeligknafeacuteloumlg og seacutergreinafeacuteloumlg iacute Skotlandi eiga fulltruacuteathornarna auk fulltruacutea fraacute hjuacutekrunarfraeligethingum lyfja-fraeligethingum tannlaeligknum og oumlethrum starfsgreinum semtengjast heilbrigethismaacutelum SIGN hefur thornegar birt 64leiethbeiningar Sjaacute lista iacute birtingarroumleth aacute www show scotnhsuksignguidelines
National Institute for Clinical Excellence (NICE) varstofnaeth iacute apriacutel 1999 sem seacuterstoumlk heilbrigethisstofnun(Special Health Authority) fyrir England og WalesStofnunin er hluti af National Health Service (NHS)og stendur aeth uacutetgaacutefu annars vegar aacute kliacuteniacuteskum leieth-beiningum (niacuteu birtar) og hins vegar heilbrigethis-taeligkniuacutettektum (health technologies (including medi-cines medical devices diagnostic techniques andprocedures)) sem nuacute eru ruacutemlega 50 talsins og maacutenaacutelgast aacute wwwniceorguk
Guideline Development Department Dutch Institutefor Healthcare Improvement (CBO) www cbonlYfir 50 skyacuterslur hafa verieth birtar en einungis aacute hol-lensku enn sem komieth er Sjaacute wwwcbonl product richtlijnen
Vakin er athygli aacute aeth meeth thornviacute aeth nota vefuacutetgaacutefuLaeligknablaethsins er auethvelt aeth smella beint aacute sloacuteethirnartil aeth komast aacute viethkomandi heimasiacuteethur
Styacuterihoacutepur umkliacuteniacuteskarleiethbeiningar
Ari Joacutehannesson laeligknir formaethur
Einar Magnuacutessonlyfjafraeligethingur
Gunnar Toacutemasson laeligknir Halldoacuter Joacutensson laeligknirHaukur Valdimarsson laeligknir Rannveig Einarsdoacutettir
kliacuteniacuteskur lyfjafraeligethingur Sigurethur Guethmundsson
landlaeligknir Sigurethur Helgason laeligknir
ritstjoacuteri Sveinn Magnuacutesson laeligknir
SEARCH NICE
Advancedraquo
Welcome to NICE Technology Appraisals Completed Appraisals 23 February 2003
E-newsletter
About NICE
TechnologyAppraisals
Clinical Guidelines
Interventionalprocedures
Clinical Audit
Board Meetings
NationalCollaborating Centres
Citizens Council
Publications
Press Office
Conference
Job Vacancies
Links
News Archive
Using this Site
English
Cymraeg
Vision Impaired
Email notify
Privacy
Completed AppraisalsAll guidance documents for completed technology appraisals are listed below
For the documents and related material click on the title in the list The list can be sorted by referencenumber title (alphabetically) wave number and date of publication - simply click on the relevant columnheading in the blue box once or twice depending on the whether you want an ascending or descending listFor more information on using the list and the terms and abbreviations used click here
No Title Wave Publication
Date Review
Date
33 Advanced Colorectal Cancer - irinotecan oxaliplatinamp raltitrexed (NO 33)
3 January 2002 April 2005
19 Alzheimers disease - donepezil rivastigmine andgalantamine (N0 19)
2 January 2001 December 2003
11 Arrhythmias - implantable cardioverter defibrillators(N0 11)
2 September 2000 September 2003
38 Asthma - inhaler devices for older children (No 38) 4 April 2002 April 2005
10 Asthma - inhalers for children under five (N0 10) 1 August 2000 August 2003
13 Attention deficit hyperactivity disorder (ADHD) -methylphenidate (N0 13)
2 October 2000 August 2003
23 Brain cancer - temozolomide (N0 23) 2 April 2001 March 2004
6 Breast cancer - taxanes (N0 6) 1 June 2000 September 2001
30 Breast cancer - taxanes - review (N0 30) R September 2001 August 2003
34 Breast cancer - trastuzumab (NO 34) 3 March 2002 April 2005
54 Breast Cancer - Vinorelbine (No 54) 3 December 2002 June 2005
5 Cervical smear tests - liquid based cytology (N0 5) 1 June 2000 May 2003
17 Colorectal cancer - laparoscopic surgery (N0 17) 2 December 2000 August 2003
40 Crohns disease (No 40) 4 March 2002 May 2005
51 Depression and anxiety - computerised cognitivebehaviour therapy (No 51)
October 2002 June 2005
21 Diabetes (type 2) - pioglitazone (N0 21) 2 March 2001 August 2002
9 Diabetes (type 2) - rosiglitazone (N0 9) 1 August 2000 August 2002
53 Diabetes - Long acting insulin analogues (No 53) 6 December 2002 November 2005
7 Dyspepsia - proton pump inhibitors (N0 7) 1 July 2000 June 2003
15 Flu - zanamivir (Relenza) (N0 15) 2 November 2000 June 2002
12 Glycoprotein IIbIIIa inhibitor guidance for acutecoronary syndromes (N0 12)
2 September 2000 September 2001
47 Glycoprotein IIbIIIa inhibitor guidance for acutecoronary syndromes - review (NO 47)
R September 2002 July 2005
Completed Appraisals - NICE
httpwwwniceorgukcatta1aspc=153 (1 of 3) [2322003 114029]
LaeligknablaethiethHliacuteethasmaacutera 8 - 201 KoacutepavogiSiacutemi 564 4104 - Fax 564 4106
9 tbl 87 aacuterg 2001
Houmlfundar
Yfirlit
Faacutemenn thornjoacuteeth aacute aeth nyacuteta vandaethefni fraacute oumlethrumNyacutetur traustsAlthornjoacuteethaheilbrigethisstofnunarinnar
Almennt
Leiethbeiningarnar hafa veriethgerethar aethgengilegar aacute vef umkliacuteniacuteskar leiethbeiningar sem er aethfinna aacute heimasiacuteethu landlaeligknisUmsjoacuten meeth gereth thorneirra hefurstyacuterihoacutepur um kliacuteniacuteskarleiethbeiningar undir stjoacutern AraJoacutehannessonar og ritstjoacuternSigurethar Helgasonar
Umraeligetha amp freacutettir
Skotar framarlega iacute flokkivieth gereth kliacuteniacuteskraleiethbeiningaIacute thornessum pistli verethur vakin athygli aacute voumlnduethu efni um kliacuteniacuteskarleiethbeiningar sem Skotar hafa unnieth og birt aacute netinu Aacute vefilandlaeligknisembaeligttisins - wwwlandlaekniris - er tengill aacute thornennanskoska vef en auk thorness er sloacuteethin birt heacuter aeth aftan
Scottish Intercollegiate Guidelines Network (SIGN) var stofnaeth 1993og eins og nafnieth gefur til kynna myndar thornetta net fjoumlldi laeligkna ogannarra heilbrigethisstarfsmanna Meethal annars eiga thornarna fulltruacutea oumllllaeligknafeacuteloumlgseacutergreinafeacuteloumlg iacute Bretlandi auk thorness sem thornarna eru fulltruacutearfraacute hjuacutekrunarfraeligethingum lyfjafraeligethingum tannlaeligknum og oumlethrumstarfsgreinum sem tengjast heilbrigethismaacutelum Houmlfuethstoumlethvar SIGN eruiacute huacutesnaeligethi skoska laeligknafeacutelagsins iacute Edinborg og nyacutetur thornessi virtastofnun mikils stuethnings laeligknafeacutelagsins og einstakra fagfeacutelaga
Faacutemenn thornjoacuteeth aacute aeth nyacuteta vandaeth efni fraacute oumlethrum
Suacute aacutekvoumlrethun styacuterihoacuteps um kliacuteniacuteskar leiethbeiningar aacute Iacuteslandi aeth bendaheilbrigethisstarfsfoacutelki aacute leiethbeiningar SIGN byggist aacute eftirtoumllduVinnulag vieth gereth SIGN leiethbeininga er mjoumlg vandaeth (val verkefnaheimildarvinna samsetning vinnuhoacutepa) og lyacutetur viethurkenndumgaeligethakroumlfum Leitast er vieth aeth koma sannreyndum (evidence based)vinnubroumlgethum iacute notkun thornannig aeth gagnast megiheilbrigethisthornjoacutenustunni Raacuteethleggingar innan leiethbeininga eru beinttengdar thorneim viacutesindalega grunni sem aeth baki liggur thornegar thorness erkostur Leiethbeiningarnar faacute mjoumlg viacuteethtaeligka kynningu sem droumlg ogboethieth er upp aacute umraeligethur (fundi) meethal heilbrigethisstarfsmanna umeinstakar leiethbeiningar aacuteethur en aeth formlegri uacutetgaacutefu kemur Aacute thornessumfundum hafa allir reacutett aacute aeth koma skoethunum siacutenum aacute framfaeligri
Framsetning leiethbeininganna thornoacutetti mjoumlg aethgengilegheildarleiethbeiningar og siacuteethan einnar til fjoumlgurra blaethsiacuteethna aacutegrip (quickreference) Faacutemenn thornjoacuteeth hefur minni toumlk aacute aeth vinna mikinn fjoumlldaleiethbeininga og henni er thornviacute nauethsynlegt aeth nyacuteta vinnu annarra seacutethorness nokkur kostur
Nyacutetur trausts Althornjoacuteethaheilbrigethisstofnunarinnar
SIGN vinnur iacute naacuteinni samvinnu vieth heilbrigethisyfirvoumlld ogsjuacuteklingasamtoumlk vieth gereth leiethbeininga Nyacuteverieth var stofnunin valin tilaeth hafa umsjoacuten meeth leiethbeiningum uacutetgefnum afAlthornjoacuteethaheilbrigethisstofnuninni og maacute aeligtla aeth thornaeth hafi komieth til vegna
Clinical Guidelines - Numerical List
Items marked are available in Acrobat format (info)
No Guideline TitleQuick
referenceguide
Fullguideline
PublicationDate
66Diagnosis and managementof childhood otitis media inprimary care (185K) (687K)
February2003
65 The immediate dischargedocument
IDDtemplate(261K) (611K)
January 2003
64
Management of patients withstroke rehabilitationprevention and managementof complications anddischarge planning
(217K) (914K)November
2002
63 British Guideline on themanagement of asthma (656K) (in sections)
January 2003
62 Prophylaxis of venousthromboembolism (290K) (11MB)
October 2002
61 Investigation ofpost-menopausal bleeding (262K) (723K)
September2002
60 Postnatal depression andpuerperal psychosis (198K) (741K)
June 2002
59Community management oflower respiratory tractinfection in adults (133K) (392K)
June 2002
58Safe sedation of childrenundergoing diagnostic andtherapeutic procedures (198K) (782K)
February2002
57 Cardiac rehabilitation(76K) (357K)
January 2002
56Prevention and managementof hip fracture in olderpeople
(225K) (974K)
January 2002
55 Management of diabetes(462K) (926K)
November2001
Clinical Guidelines - Numerical List
httpwwwsignacukguidelinespublishednumlisthtml (1 of 4) [2322003 120120]
131313
13131313
13
13
Scottish Intercollegiate Guidelines NetworkThe British Thoracic Society
British Guideline on theManagement of Asthma
British Association for Accident and Emergency
Medicine
General PracticeAirways Group
Royal College of Paediatricsand Child HealthRoyal Paediatric
Respiratory Society
Royal College of Physiciansof London
Cya
n D
ON
O
Information on the full guideline produced by the National Collaborating Centre for Mental Healthfrom which the NICE guideline has been prepared is given in Section 6 of the NICE guideline
Clinical Guideline 1SchizophreniaCore interventions in the treatment and management of schizophrenia in primary and secondary care
Issue dateDecember 2002
The algorithms and pathways to care on this poster form part of the NICE guideline onschizophrenia (see above) Copies of the NICE guideline can be obtained free of charge from theNICE website (wwwniceorguk) and from the NHS Response Line (phone 0870 1555 455 andquote reference number N0176) A version for people with schizophrenia their advocates andcarers and the public called Treating and managing schizophrenia (core interventions)is alsoavailable from the website and the NHS Response Line (quote reference number N0177 for anEnglish-only copy and N0178 for a copy that has the text in both English and Welsh)
This guidance is written in the following contextThis guidance represents the view of the Institute which was arrived at after carefulconsideration of the evidence available Health professionals are expected to take it fully intoaccount when exercising their clinical judgment The guidance does not however override theindividual responsibility of health professionals to make decisions appropriate to thecircumstances of the individual patient in consultation with the patient andor guardian or carer
National Institute for Clinical Excellence
11 StrandLondon WC2N 5HR
wwwniceorguk
ISBN 1-84257-257-1Published by the National Institute for Clinical ExcellenceDecember 2002Design by Anytime After 9 LtdPrinted by Abba Litho Sales Limited London
copyCopyright National Institute for Clinical Excellence December 2002 All rights reserved This material may be freelyreproduced for educational and not-for-profit purposes within the NHS No reproduction by or for commercialorganisations is allowed without the express written permission of the National Institute for Clinical Excellence
SchizophreniaCore interventions in the treatment andmanagement of schizophrenia in primary andsecondary care
Clinical practice algorithms and pathways to careDecember 2002
Developed by the National Collaborating Centre for Mental Health
Guidance on theuse of debridingagents and specialist wound care clinics fordifficult to healsurgical wounds
Tech
no
log
y A
pp
rais
al G
uid
ance
- N
o2
4
April 2001
Summary and Conclusions
Prevention Diagnosisand Treatment of VenousThromboembolismA Systematic Review
The Swedish Council on Technology Assessment in Health Care
CARDIACREHABILITATIONSUMMARY ANDRESOURCE KIT
BEST PRACTICEEVIDENCE-BASEDGUIDELINE
AUGUST 2002
Exercise-Based Cardiac Rehabilitation Programs for Coronary Artery Disease A Systematic Clinical and Economic Review
Technology Report
Issue 34 March 2003
v
assessment From these 99 articles 5 new EX CR trials and 5 new CCR trials were included in our review The 10 new trials are more recent than those included in the Cochrane review which included 36 trials That brings the total number of trials analysed in our meta-analysis to 46 The clinical meta-analysis found that CCR showed a trend toward reduction in total mortality although this was not statistically significant (RR 087 95 CI 074 to 102) However cardiac mortality was reduced (RR 080 95 CI 065 to 099) EX CR reduced total mortality (RR 076 95 CI 059 to 098) and reduced cardiac mortality (RR 073 95 CI 056 to 096) Health related quality of life (HRQoL) outcomes were not pooled but there was evidence of a consistent improvement in HRQoL across the nine trials reporting this outcome although few studies showed improvement above that measured in the usual care groups Meta-regression analysis failed to demonstrate the presence of any significant sub-group effects Sub-groups analysed included EX CR or CCR duration of program intensity of program follow-up period all post MI or other than just MI patients gender age trials pre- or post-1995 and quality of trials In the review of economic evidence 614 potentially relevant studies were found Of these 64 were retrieved for full text assessment and 6 were ultimately included in the review Three were full economic evaluations and 3 were cost studies Only 1 included study was RCT-based It was an economic evaluation located in Canada and concluded that an eight-week supervised exercise plus counselling program cost US$9200 per QALY and US$21800 per life-year gained during the year of follow-up Another Canadian-based economic evaluation found that it costs less than US$15000 per year of life saved for a supervised CR program for men A US study found that it cost US$4950 per year of life saved through CR The cost studies based in Sweden and the US concluded that CR may be cost saving compared to standard care for patients with CAD due to lower rehospitalization rates and lower mean patient costs Conclusions The systematic review of clinical evidence supports the findings of the previous Cochrane review in that CR which includes exercise has beneficial effects on cardiac mortality and total mortality (although the trend for CCR on total mortality was not significant) It appears that CCR has a somewhat more positive effect overall on risk factors than EX CR Few studies have examined the impact of CR on HRQoL and in those that have there was a non-significant trend that CR which includes exercise enhances quality of life relative to usual care Although recent trials have increasingly recruited patients who have had revascularization or angina the representation of women and the elderly in the trials remains poor The long-term (ie 10 years or more) mortality benefit of CR tends to diminish This may be associated with a reduction in exercise behaviour The results of the included economic studies were consistent in that the three full economic evaluations all suggested CR which includes exercise is cost-effective and the three cost studies all suggested CR which includes exercise may reduce costs to health care systems due to reduced rehospitalization and drug utilization Although the cost studies suggest that over time cost savings would result from switching to CR from standard care in the short term there would likely be a significant budget impact For example at an average cost of C$1000 per patient making supervised cardiac rehabilitation standard practice for Canadian CAD patients could increase short run annual expenditures in Canada by C$225 million
LaeligknablaethiethHliacuteethasmaacutera 8 - 201 KoacutepavogiSiacutemi 564 4104 - Fax 564 4106
5 tbl 87 aacuterg 2001
Houmlfundar
Anna OacutelafsdoacutettirBjoumlrnsson
Yfirlit
AethdragandinnLeiethbeiningar
Almennt
Umraeligetha amp freacutettir
Gaeligethi laeligknisthornjoacutenustu aukinmeeth vefi um kliacuteniacuteskarleiethbeiningarAacute vegum landlaeligknisembaeligttisins hefur verieth unnieth aeth thornviacute aacute undanfoumlrnummisserum aeth byggja upp vef undir heitinu Kliacuteniacuteskrar leiethbeiningar THORNegarer komieth talsvert efni aacute vefinn en 26 vinnuhoacutepar hafa unnieth aeth gereth thornessSjouml thorneirra hafa thornegar uacutetbuacuteieth efni sem er komieth aacute vefinn yacutemist tilbuacuteieth eetha iacutevinnslu Alls hafa um 70 laeligknar tekieth thornaacutett iacute vinnslu efnisins auk foacutelks uacuteroumlethrum heilbrigethissteacutettum Vefurinn er vistaethur aacute heimasiacuteethulandlaeligknisembaeligttisins wwwlandlaekniris undir LeiethbeiningarEftirlit aacutevalstiku vinstra megin aacute siacuteethunni Auk thorness hefur thornaeth efni sem er tilbuacuteiethverieth gefieth uacutet aacute geisladiski aacutesamt vefnum Lyfjavali 2000 Iacute biacutegereth erennfremur aeth helstu aacutehersluatriethi sem birt eru aacute yfirlitssiacuteethu hversmaacutelaflokks aacute vefnum verethi uacutetbuacutein sem ploumlstueth minnisbloumleth THORNaeth verkefni ernokkueth dyacutert og verethur sennilega haacuteeth thornviacute aeth fjaacutermagn faacuteist til verksins
Laeligknablaethieth hefur nuacute kynningu aacute thornviacute efni sem er aeth finna aacute vefnum meeththornviacute aeth taka ritstjoacutera efnisins Sigureth Helgason laeligkni tali Pistlar um hineinstoumlku viethfangsefni sem hoacuteparnir hafa tekieth fyrir veretha birtir iacuteLaeligknablaethinu aacute naeligstunni Styacuterihoacutepur undir forystu Ara Joacutehannessonarlaeligknis hefur yfirumsjoacuten meeth starfi thornessu og moacutetar verklag og stefnu enAri er formaethur fagraacuteeths Laeligknafeacutelags Iacuteslands um mat aacute laeligkningataeligkni oggereth kliacuteniacuteskra leiethbeininga Iacute hoacutepnum sitja auk thorneirra Sigurethar og AraRannveig Einarsdoacutettir kliacuteniacuteskur lyfjafraeligethingur Sigurethur Guethmundssonlandlaeligknir og laeligknanir Haukur Valdimarsson Oacutettar Bergmann SigurethurOacutelafsson Runoacutelfur Paacutelsson Magnuacutes Joacutehannsson og Sveinn Magnuacutesson Iacutehoacutepnum eru fulltruacutear uacuter yacutemsum seacuterfraeligethigreinum laeligknisfraeligethinnar auk thornesssem fulltruacutei unglaeligkna iacute hoacutepnum er tengiliethur vieth stoacuteran hoacutep unglaeligkna Ennmeiri fjoumllbreytni maacute greina ef litieth aacute allt thornaeth foacutelk sem tekur thornaacutett iacute vinnuhinna einstoumlku hoacutepa og sumir eru iacute fleiri en einum hoacutepi Markmiethieth meethkliacuteniacuteskum leiethbeiningum er fyrst og fremst aeth baeligta gaeligethi laeligknisthornjoacutenustueftir thornviacute sem kostur er
Aethdragandinn
Aethdragandinn aeth gereth kliacuteniacuteskra leiethbeininga aacute netinu er saacute aeth leitaeth var tilSigurethar Helgasonar heilsugaeligslulaeligknis iacute Aacuterbaelig siacuteethla aacuters 1999 og hannbeethinn aeth taka aeth seacuter ritstjoacutern thornessa vefjar Hann var ekki meeth oumllluoacutekunnur sliacutekri uppbyggingu eftir aeth hafa unnieth aeth hliethstaeligethu verkefni semfjallaethi um Lyfjaval Fagraacuteeth Laeligknafeacutelags Iacuteslands undir forystu PaacutelmaJoacutenssonar hafethi thornaacute um eins aacuters skeieth unnieth aeth tilloumlgum um gereth kliacuteniacuteskraleiethbeiningar og sett fram moacutetaethar hugmyndir thornar aeth luacutetandi (Laeligknablaethieth1999 851004) THORNaeth sem yacutetti thornessu af staeth var aeth iacute loumlndunum allt iacutekringum okkur er mikieth af sliacuteku efni Vieth houmlfethum dregieth lappirnar svoliacutetiethiacute thornessum efnum og laeligknar sem soacutett hafa menntun siacutena til yacutemissa landa hafanotast vieth thornaeligr leiethbeiningar sem thornekkja uacuter naacutemi siacutenu og stoumlrfum erlendisSigurethur var fyrst raacuteethinn til eins aacuters og aeth thornviacute loknu var raacuteethning hans
Aacute thornessari siacuteethu eru aeth finna tengla aacute helstu kliacuteniacutesku leiethbeiningarnar fyrir krabbamein ATH Siacuteethan er iacute vinnslu
StaethurSjuacutekdoacutemaflokkur
SOR (The SOR Project of the National Federation of French Cancer Centers Clinical PracticeGuidelines in Oncology)
GynecologicalCancers
GastrointestinalCancer
Hemopathy Head and NeckCancer
Lung Cancer Other cancertypes
Ovarian Cancer Carcinoma of thecolon
Hodgkins Disease Malignant tumours ofthe salivary glands
Malignantmesothelioma
Epithelial tumours ofthe thymus
Carcinoma of thecervix
Hepatocellularcarcinoma
Epidermoid cancersof the oropharynx
Osteosarcoma
Cancer of theendometrium
Carcinoma of theoesophagus
Cancer of the rectum
Cancer Care OntarioBreastCancer
GastrointestinalCancer
GenitourinaryCancer
GynecologicalCancer
Head andNeckCancer
Hematology LungCancer
ApprovedPracticeGuidelines
Approved PracticeGuidelines
Approved PracticeGuidelines
Approved PracticeGuidelines
ApprovedPracticeGuidelines
Approved PracticeGuidelines
ApprovedPracticeGuidelines
PracticeGuidelines inProgress
Practice Guidelinesin Progress
Practice Guidelinesin Progress
PracticeGuidelines inProgress
PracticeGuidelines inProgress
PracticeGuidelines inProgress
PracticeGuidelines inProgress
ApprovedEvidenceSummaries
Approved EvidenceSummaries
ApprovedEvidenceSummaries
ApprovedEvidenceSummaries
ApprovedEvidenceSummaries
ApprovedEvidenceSummaries
EvidenceSummaries inProgress
EvidenceSummaries inProgress
EvidenceSummaries inProgress
EvidenceSummaries inProgress
EvidenceSummaries inProgress
EvidenceSummaries inProgress
Melanoma Neuro-OncologyPediatricCancer
Sarcoma SupportiveCare
SystemicTreatment
ApprovedPracticeGuidelines
Approved PracticeGuidelines
Practice Guidelines Approved PracticeGuidelines
PracticeGuidelines
Approved PracticeGuidelines
PracticeGuidelines inProgress
Practice Guidelinesin Progress
PracticeGuidelines inProgress
PracticeGuidelines inProgress
ApprovedEvidenceSummaries
Approved EvidenceSummaries
EvidenceSummaries inProgress
EvidenceSummaries inProgress
ASCO American Society of Clinical Oncology BreastCancer
ColorectalCancer
LungCancer
MultipleMyeloma
TumorMarkers
AntiemeticAnemiaplatelettransfusions
ColonyStimulatingFactorsProtecants
SOR
httpwwwkmlshiskl1htm (1 of 4) [2422003 143742]
The Role ofBisphosphonatesin Breast Cancer
2000 Updateof ColorectalCancerSurveillanceGuidelines
UnresectableNon-Small-CellLung Cancer
The Role OfBisphosphonatesIn MultipleMyeloma
1997 Update ofRecommendationsfor the Use ofTumor Markers inBreast andColorectal Cancer
Recommendations forthe Use of Antiemetics
1996 Update ofRecommendations forthe Use ofHematopoieticColony-StimulatingFactors
RecommendedBreast CancerSurveillance
RecommendedColorectalCancerSurveillanceGuidelines
Tumor Markers inBreast andColorectal Cancer
Use of Epoetin inPatients With Cancer
2000 Update ofRecommendations forthe Use ofHematopoieticColony-StimulatingFactors
PostmastectomyRadiotherapy
Platelet Transfusion forPatients With Cancer
Use of HematopoieticColony-StimulatingFactorsEvidence-BasedPractice Guidelines
1998 Update ofRecommendedBreast CancerSurveillanceGuidelines
The Use ofChemotherapy andRadiotherapyProtectants
NICE (National Institute for Clinical Excellence)Brain Cancer Breast
CancerCervicalSmear Tests
ColorectalCancer
Leukaemia Lung Cancer Lymphoma
Brain cancer -temozolomide(N0 23)
Breast cancer -taxanes (N0 6)
Cervical smeartests - liquidbased cytology(N0 5)
AdvancedColorectalCancer -irinotecanoxaliplatin ampraltitrexed (NO33)
Leukaemia(chronic myeloid)- imatinib (N0 50)
Lung cancer -docetaxelpaclitaxelgemcitabine andvinorelbine (N026)
Lymphoma(follicularnon-Hodgkins) -rituximab (no 37)
Breast cancer -taxanes - review(N0 30)
Colorectalcancer -laparoscopicsurgery (N0 17)
Leukaemia(lymphocytic) -fludarabine (N029)
Breast cancer -trastuzumab (NO34)
Breast Cancer -Vinorelbine (No54)
OvarianCancer
PancreaticCancer
Ovarian cancer(advanced) -PLDH (Caelyx)(No45)
Pancreaticcancer -gemcitabine (N025)
Ovarian Cancer -paclitaxel (No55)
Ovarian cancer -taxanes (N0 3)
Ovarian cancer -topotecan (N028)
SOR
httpwwwkmlshiskl1htm (2 of 4) [2422003 143742]
The Periodic Maintenance Lubrication Intervals schedule is taken directly from a 1980 edition Suzuki FS50 factory owners manual
Before starting any work always consult the manual for your scooters model amp year and be sure you know what youre doing
MethodologyQuestions set by a multidisciplinary groupLiterature searches using these questionsMeta-analyses randomised controlled trials
required for A recommendationParticular attention paid to
ndash study size ITT analysesndash predefined goals
Levels of Evidence for Databull Level 1 Randomized controlled trials (RCTs) with
sufficient numbers or good quality meta-analyses based on RCTs
bull Level 2 RCTs with smaller numbers (therefore insufficient power)
bull Level 3 Non-randomized controlled or cohort studies case series case-controlled or cohort studies cross sectional or high quality retrospective studies
bull Level 4 Evidence based on the published opinion of expert committees for example consensus guidelines committees
bull Level 5 Evidence which expresses the opinion of the committee member(s) who have reviewed the literature and guidelines following discussion with peers
See also Italian
COCHRANE DEPRESSION ANXIETYAND NEUROSIS GROUP
Abstracts of Cochrane Reviews
The Cochrane Library Issue 1 2003The full text of these reviews and protocols is available in The Cochrane Library
indicates the review is new in the current release of the Library indicates the review has been substantially amended since the last issue of the
Library
Note Protocols are the introduction objectives materials and methods for reviewscurrently being prepared and do not therefore have abstracts
Whats new in this issue
Search abstracts
Browse by Review Group
Browse alphabetical list oftitles
About The Cochrane Library
Reviews
Active placebos versus antidepressants for depression (Cochrane Review)
Antidepressant and benzodiazepine for major depression (Cochrane Review)
Antidepressant treatment for post-natal depression (Cochrane Review)
Antidepressants for depression in medical illness (Cochrane Review)
Antidepressants versus placebo for the depressed elderly (Cochrane Review)
Antidepressants versus psychological treatments and their combination for bulimianervosa (Cochrane Review)
Antidepressants versus placebo for people with bulimia nervosa (Cochrane Review)
Cognitive behaviour therapy for chronic fatigue syndrome in adults (Cochrane Review)
Drugs versus placebo for dysthymia (Cochrane Review)
Effectiveness and cost effectiveness of counselling in primary care (Cochrane Review)
Interventions for pathological gambling (Cochrane Review)
Interventions for preventing eating disorders in children and adolescents (CochraneReview)
Interventions for vaginismus (Cochrane Review)
Kava extract for treating anxiety (Cochrane Review)
Lithium for maintenance treatment of mood disorders (Cochrane Review)
Melatonin for the prevention and treatment of jet lag (Cochrane Review)
Pharmacotherapy for Posttraumatic Stress Disorder (Cochrane Review)
Psychological debriefing for preventing post traumatic stress disorder (PTSD) (CochraneReview)
Psychosocial and pharmacological treatments for deliberate self harm (CochraneReview)
COCHRANE DEPRESSION ANXIETY AND NEUROSIS GROUP abstracts
httpwwwupdate-softwarecomabstractsg240indexhtm (1 of 3) [2242003 203324]
Psychotherapy for bulimia nervosa and binging (Cochrane Review)
Selective serotonin reuptake inhibitors (SSRIs) for depression (Cochrane Review)
St Johns wort for depression (Cochrane Review)
The use of antidepressants for Generalized Anxiety Disorder (This review has beenwithdrawn by the editorial group Abstract not available)
Transcranial magnetic stimulation for treating depression (Cochrane Review)
Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versustricyclic antidepressants (TCAs) (Cochrane Review)
Tricyclic drugs for depression in children and adolescents (Cochrane Review)
Tryptophan and 5-Hydroxytryptophan for Depression (Cochrane Review)
Valproate for acute mood episodes in bipolar disorder (Cochrane Review)
Valproic acid valproate and divalproex in the maintenance treatment of bipolar disorder(Cochrane Review)
Protocols
5HT-1 agonists for generalized anxiety (Cochrane Protocol)
A comparison of active drugs for the treatment of dysthymia (Cochrane Protocol)
Acupuncture for depression (Cochrane Protocol)
Amitriptyline versus other tricyclic drugs and selective serotonin reuptake inhibitors(SSRIs) for depression (Cochrane Protocol)
Antidepressant dose-increase for non-responders to a standard dose for depression(Cochrane Protocol)
Antidepressants alone versus psychotherapy alone for depression (Cochrane Protocol)
Antidepressants for depressed elderly (Cochrane Protocol)
Antidepressants for bipolar depression (Cochrane Protocol)
Benzodiazepines for generalized anxiety (Cochrane Protocol)
Brief cognitive-behavioural therapies versus other brief psychological therapies fordepression (Cochrane Protocol)
Brief psychological therapies versus treatment as usual for depression (CochraneProtocol)
Carbamazepine for bipolar affective disorders (Cochrane Protocol)
Combinations of pharmacotherapy and psychotherapy for depression (CochraneProtocol)
Duration of treatment with antidepressants in depressive disorder (Cochrane Protocol)
Electroconvulsive therapy for depressed elderly (Cochrane Protocol)
Exercise therapy for depression and other neurotic disorders (Cochrane Protocol)
Exercise therapy for chronic fatigue syndrome (Cochrane Protocol)
Folate for depressive disorders (Cochrane Protocol)
Gabapentin in the treatment of acute affective episodes in bipolar disorderefficacy andacceptability (Cochrane Protocol)
Individual psychotherapy in the outpatient treatment of adults with anorexia nervosa(Cochrane Protocol)
Initial high dose versus standard dose of antidepressants for depression (CochraneProtocol)
Inositol for depressive disorders (Cochrane Protocol)
COCHRANE DEPRESSION ANXIETY AND NEUROSIS GROUP abstracts
httpwwwupdate-softwarecomabstractsg240indexhtm (2 of 3) [2242003 203324]
Home | Support | Links | The Cochrane Collaboration | DataProviders Pages
Search
The Cochrane Library
About
Log on
Whats in
Abstracts of CochraneReviews
How to get access
Known problems ampchange requests
Demo amp Screensaver
Document Delivery
Feedback
La Cochrane LibraryPlus en espantildeol
The WHOReproductive HealthLibrary
The NationalResearch Register
The Cancer Library
Acluster
Evidence BasedMedicine Guidelines
Meerkat
CASPEvidence-basedHealth Care
Now published by Wiley
Available soon through WileyInterScience
The Cochrane Library
No one can keep up to date with therelevant evidence in their field ofinterest The major bibliographicdatabases cover less than half theworlds literature and are biased towardsEnglish language publications Of theevidence available in the majordatabases only a fraction can be foundby the average searcher Textbookseditorials and reviews which have notbeen prepared systematically may beunreliable Much evidence isunpublished but unpublished evidencemay be important More easilyaccessible research reports tend toexaggerate the benefits of interventions
The Cochrane Library solves many ofthese problems Published on aquarterly basis and made available bothon CD-ROM and the Internet (see Howto get access) it is the best singlesource of reliable evidence about theeffects of health care
The Cochrane Library consists of aregularly updated collection ofevidence-based medicine databasesincluding The Cochrane Database ofSystematic Reviews - evidence basedsystematic reviews prepared by theCochrane Collaboration which providehigh quality information to peopleproviding and receiving care and those
AbstractsThe Abstracts of Cochrane Reviews areavailable without charge and can bebrowsed or searched
Quick Reference CardA quick reference card offering usefulinformation and tips about using the newinternet version of The Cochrane Library isnow available in PDF format Click here todownload a copy Please acknowledgeUpdate Software as the source of this guideif you wish to distribute it for trainingpurposes
Further useful reference materialNICS user guide to The Cochrane LibraryCRD training and reference material
Provisional Publication Dates for 2003
Issue 1 2003 20 January 2003Issue 2 2003 22 April 2003Issue 3 2003 21 July 2003Issue 4 2003 20 October 2003
About The Cochrane Library
httpwwwupdate-softwarecomcochranedefaulthtm (1 of 2) [2242003 203417]
A substantive amendment to this systematic review was last made on 18 November 2002 Cochrane reviews are regularly checked and updated if necessary
Background Bipolar disorder is a common debilitating illness characterised by acute affective episodes with full or partial inter-episode remission Effective and acceptable treatment of acute episodes is required Valproate has become a leading adjunctive and alternative mood stabilising treatment to lithium in bipolar disorder
Objectives To determine the efficacy and acceptability of valproate in the treatment of acute episodes of bipolar disorder
Search strategy The search included the Cochrane Collaboration Depression Anxiety and Neurosis Controlled Trials Registrar (CCDANCTR) the Cochrane Controlled Clinical Trials Register (CCTR) reference lists of relevant papers and books and contact with authors of trials experts and pharmaceutical companies
Selection criteria Randomised controlled trials comparing valproate with placebo other mood stabilisers and antipsychotic medication in the treatment of any bipolar affective episode Participants were of both sexes of all ages with a diagnosis of bipolar affective disorder approximating to ICD 10 Code F31and DSM IV 296
Data collection and analysis Methodological quality was assessed independently by two reviewers blind to the authorship and source of papers
Ten randomised controlled trials were found comparing valproate with other interventions in mania None was found examining its use in depression or mixed affective episodes Data were extracted on the main outcome failure to respond by the end of the study assessed by a less than 50 reduction in the Young Mania Rating Scale or the SADS-S mania scale Three trials (316 participants) compared valproate with placebo Three trials (158 participants) compared valproate with lithium Two trials (363 participants) compared valproate with olanzapine One trial (36 participants) compared valproate with haloperidol Two trials (59 patients) compared valproate with carbamazepine
Acceptability of treatment was estimated using the outcome measure total number of subjects withdrawing from the study Three trials (321 patients) contributed to the comparison between valproate and placebo two studies (144 patients) contributed to the comparison with lithium One study (30 patients) provided data on this outcome in the comparison between valproate and carbamazepine Pooled relative risks (with 95 confidence intervals) were calculated using fixed effect approaches
Main results Valproate was more efficacious than placebo (RRR 38 RR 062
From The Cochrane Library Issue 1 2003 Oxford Update Software Ltd All rights reserved
Valproate for acute mood episodes in bipolar disorder (Cochrane Review)
Macritchie K Geddes JR Scott J Haslam D de Lima M Goodwin G
ABSTRACT
Order full review
View andor submit comments
Whats new in this issue
Search abstracts
Browse by Review Group
Browse alphabetical list of titles
About The Cochrane Library
Page 1 of 2Valproate for acute mood episodes in bipolar disorder (Cochrane Review)
2242003httpwwwupdate-softwarecomabstractsab004052htm
95 CI 051 to 077) in the treatment of mania There was no significant difference between valproate and lithium (RRI 5 RR 105 95 CI 074-150) or between valproate and carbamazepine (RRR 34 RR 066 95 CI 038 to 116) Valproate was less effective than olanzapine (failure to achieve clinical response RRI 25 RR 125 95 CI 101 to 154 average of 28 point less change on the Mania Rating Scale (95 CI 083 to 479) There were no significant differences in acceptability as measured by total number of subjects withdrawing from the study There were significant differences in the side effect profiles of valproate and olanzapine with more sedation and weight gain on olanzapine
Reviewers conclusions There is consistent if limited evidence to suggest that valproate is an efficacious treatment for acute mania Valproate may be less effective than olanzapine but may cause less sedation and weight gain More well designed randomised controlled trials investigating the relative efficacy and acceptability of valproate in the treatment of the full range of acute affective episodes occurring in bipolar disorder are required
Citation Macritchie K Geddes JR Scott J Haslam D de Lima M Goodwin G Valproate for acute mood episodes in bipolar disorder (Cochrane Review) In The Cochrane Library Issue 1 2003 Oxford Update Software
This is an abstract of a regularly updated systematic review prepared and maintained by the Cochrane
Collaboration The full text of the review is available in The Cochrane Library (ISSN 1464-780X)
The Cochrane Library is prepared and published by Update Software Ltd All rights reserved
See wwwupdate-softwarecom or contact Update Software infoupdatecouk for information on subscribing to The Cochrane Library in your area
Update Software Ltd Summertown Pavilion Middle Way Oxford OX2 7LG UK (Tel+44 1865 513902 Fax+44 1865 516918)
File Reference AB004052
Page 2 of 2Valproate for acute mood episodes in bipolar disorder (Cochrane Review)
2242003httpwwwupdate-softwarecomabstractsab004052htm
Limit to
1 PREMEDLINE Ulrich ML Rotzinger S Asghar SJ Jurasz P Tanay VA Dunn SM Radomski M Greenshaw A Silverstone PH Effects of dextroamphetamine lithium chloride sodium valproate and carbamazepine on intraplatelet Ca2+ levels [Journal Article] Journal of Psychiatry amp Neuroscience 28(2)115-25 2003 March
bull
2 MEDLINE Oluboka OJ Bird DC Kutcher S Kusumakar V A pilot study of loading versus titration of valproate in the treatment of acute mania [Clinical Trial Journal Article Randomized Controlled Trial] Bipolar Disorders 4(5)341-5 2002 Oct UI 12479668
bull
Pre-MEDLINE MEDLINE
Search History Results Display
1(controlled or randomized or double blind or sham or placebo)mp [mp=ti ab rw sh]
332920
2 (depression or bipolar or depressed)mp [mp=ti ab rw sh] 161368
3 valproatemp [mp=ti ab rw sh] 3958
4 2 and 3 377
5 1 and 4 104
6 limit 5 to human [Limit not valid in Pre-MEDLINE records were retained] 103
7 6 not reviewmp [mp=ti ab rw sh] 84
Enter Keyword or phrase
Abstracts English Language Review Articles EBM Reviews Human Latest Update Ovid Full Text Available
gfedc gfedc gfedc gfedc gfedc
gfedc gfedc
Publication Year - - -
PREMEDLINE ltApril 22 2003gt (1 records) bull MEDLINE lt1966 to April Week 3 2003gt (83 records)
Results of your search 6 not reviewmp [mp=ti ab rw sh] Citations displayed 1-10 of 84 Go to Record 1 Citation Manager bull Help bull Logoff
gfedc
gfedc
Page 1 of 3Ovid Search Form
2342003httpgateway2ovidcomovidwebcgi
A substantive amendment to this systematic review was last made on 18 November 2002 Cochrane reviews are regularly checked and updated if necessary
Background Constraints on resources and time often render treatments for anxiety such as psychological interventions impracticable while synthetic anxiolytic drugs are effective but are often burdened with adverse events Options which are effective and safe would be of considerable interest and a welcome addition to the therapeutic repertoire
Objectives To assess the effectiveness and safety as reported in rigorous clinical trials of kava extract compared with placebo for treating anxiety
Search strategy All publications describing (or which might describe) randomised double-blind placebo-controlled trials of kava extract for anxiety were sought through electronic searches on EMBASE MEDLINE AMED (British Library) CISCOM (Research Council for Complementary Medicine London) CentralCCTR and CCDANCTR The search terms that were used were kava kawa kavain Piper methysticum and Rauschpfeffer (German common name for Piper methysticum) Additionally manufacturers of kava preparations and experts on the subject were contacted and asked to contribute published and unpublished material Hand-searches of relevant medical journals (Erfahrungsheilkunde 1996 - 2002 Forsch Komplementaumlrmed Klass Naturheilkd 1994 - 2002 Phytomed 1994 - 2002 Alt Comp Ther 1995 - 2002) conference proceedings (eg FACT - Focus on Alternative and Complementary Therapies 1996 - 2002) and our own files were conducted The searches were updated to August 2002 No restrictions regarding the language of publication were imposed
Selection criteria To be included studies were required to be randomised controlled trials (RCTs) ie trials with a randomised generation of allocation sequences and conducted placebo-controlled and double-blind ie trials with blinding of patients and care providers Trials using oral preparations containing kava extract as the only component (mono-preparation) were considered Trials using single constituents of kava extract alone assessing kava extract as one of several active components in a combination preparation or as a part of a combination therapy were excluded
Data collection and analysis Data were extracted systematically according to patient characteristics interventions and results Methodological quality of all trials was evaluated using the standard scoring system developed by Jadad and colleagues The screening of studies selection data extraction validation and the assessment of methodological quality were performed independently by the two reviewers Disagreements in the evaluation of individual trials were resolved through discussion
From The Cochrane Library Issue 1 2003 Oxford Update Software Ltd All rights reserved
Kava extract for treating anxiety (Cochrane Review) Pittler MH Ernst E
ABSTRACT
Order full review
View andor submit comments
Whats new in this issue
Search abstracts
Browse by Review Group
Browse alphabetical list of titles
About The Cochrane Library
Page 1 of 2Kava extract for treating anxiety (Cochrane Review)
2242003httpwwwupdate-softwarecomabstractsab003383htm
whats new
facts amp fallacies
required reading
medical students
things you can do
take the pledge
pen amnesty
paraphernalia
resources - news archives - patient assistance - links - users guide - slide presentation
join or contribute
comments
about us
Underlined text links to on-line full-text or medline abstractFor an exhaustive bibliography of everything having to do with pharmaceuticalpromotion visit Healthy Skepticism
Original StudiesAttitudes and Practices
Gibbons RV Landry FJ Blouch DL et al A comparison of physicians and patientsattitudes toward pharmaceutical industry gifts JGIM 1998 13151-154
Hodges B Interactions with the pharmaceutical industry experiences and attitudes ofpsychiatry residents interns and clerks CMAJ 1995 Sep 1153(5)553-9
Lurie N Rich EC Simpson DE et al Pharmaceutical representatives in academicmedical centers Interaction with faculty and housestaff J Gen Int Med 19905240-243
Mainous III AG Hueston WJ Rich EC Patient perceptions of physician acceptance ofgifts from the pharmaceutical industry Arch Fam Med 4 1995 335-9
McKinney WP Schiedermayer DL Lurie N et al Attitudes of internal medicine facultyand residents toward professional interaction with pharmaceutical sales representativesJAMA 1990 Oct 3264(13)1693-7
Steinman MA Shlipak MG McPhee SJ Of principles and pens attitudes and practicesof medicine housestaff toward pharmaceutical industry promotions Am J Med 2001May110(7)551-7
Influence on Behavior Beliefs and AttitudesAvorn J Chen M Hartley R Scientific versus commercial sources of influence on theprescribing behavior of physicians Am J Med 1982734-8
Caudill TS Johnson MS Rich EC McKinney WP Physicians pharmaceutical salesrepresentatives and the cost of prescribing Arch of Fam Med 19965201-206
Chew LD et al A Physician Survey of the Effect of Drug Sample Availability onPhysicians Behavior J Gen Int Med 200015 478-483
Chren MM Landefeld CS Physicians behavior and their interaction with drugcompanies JAMA 1994271684-689
Orlowski JP and Wateska L The effects of pharmaceutical firm enticements on physicianprescribing patterns Chest 1992 102270-273
Peay MY Peay ER The role of commercial sources in the adoption of a new drug SocSci Med 1988261183-9
Bias in Promotional MaterialsStryer D and Bero LA Characteristics of materials distributed by drug companies Anevaluation of appropriateness J Gen Int Med 199611575-583
Ziegler MG Lew P Singer BC The accuracy of drug information from pharmaceuticalsales representatives JAMA 19952731296-1298Comments in JAMA19952741267-1268
Wilkes MS Doblin BH Shapiro MF Pharmaceutical advertisements in leading medicaljournals expertsrsquo assessments Ann Intern Med 1992116912-9
Pharmaceutical SamplesTong KL Lien CY Do pharmaceutical representatives misuse their drug samples CanFam Physician 1995411363-1366
No Free Lunch Required Reading
httpwwwnofreelunchorgrequiredhtm (1 of 2) [2242003 215747]
Westfall JM McCabe H Nicholas RA Personal use of drug samples by physicians andoffice staff JAMA 1997278141-143 Comments in JAMA 19982791698-99
Systematic ReviewsLexchin J What information do physicians receive from pharmaceutical representativesCan Fam Phys 199743941-945
Lexchin J Interactions between physicians and the pharmaceutical industry what doesthe literature say CMAJ 1993 1491401-7
Wazana A Physicians and the Pharmaceutical Industry Is a gift ever just a gift JAMA2000 283 No 3
Commentaries essays and editorialsChren MM Landefeld S Murray TH Doctors drug companies and gifts JAMA19892623448-51
Griffith D Reasons for not seeing drug reps BMJ 1999 319 69-70
Lexchin J Doctors and detailers Therapeutic education or pharmaceutical promotionInt J Health Services 198919663-679
Shaughnessy AF and Slawson DC Pharmaceutical representatives (editorial) BMJ19963121494
Shaughnessy AF Slawson DC Bennett JH Separating the wheat from the chaffidentifying fallacies in pharmaceutical promotion J of Gen Int Med 1994 10563-8
Waud DR Pharmaceutical promotions--a free lunch N Engl J Med 1992327351-3
Wolfe SM Why do American drug companies spend more than $12 billion a yearpushing drugs Is it education or promotion J of Gen Int Med 199611 637-9
Position PapersAmerican College of Physicians-American Society of Internal Medicine Position PaperPhysician-Industry Relations Part 1 Individual Physicians Ann Intern Med2002136396-402
American College of Physicians-American Society of Internal Medicine Position PaperPhysician-Industry Relations Part 2 Organizational Issues Ann Intern Med2002136403-406
American College of Physicians Position Paper Ethics Manual 4th edition April 11998
Canadian Medical Association Policy Summary Physicians and the pharmaceuticalindustry CMAJ Feb 1 1992
Council on Ethical and Judicial Affairs American Medical Association Gifts tophysicians from industry JAMA 1991 261 501
Council on Ethical and Judicial Affairs American Medical Association Guidelines ongifts to physicians from industry an update Food and Drug Law Journal 199247445-458
Royal College of Physicians The Relationship between physicians and thepharmaceutical industry Journal of the Royal College of Physicians of London 198620(4)235-42
copy 2002 No Free Lunch
No Free Lunch Required Reading
httpwwwnofreelunchorgrequiredhtm (2 of 2) [2242003 215747]
The National The National Institute for Clinical Institute for Clinical ExcellenceExcellenceNICEwwwniceukorg
Wisdom Teeth Removal
These should not be removed unless they are diseased or causing problems This means that patients will not be exposed to unnecessary risks of surgery and that
around pound5million capacity will be released
The Chief Dental Officers in both England amp Wales supported this guidance
SEARCH NICE
Advancedraquo
Welcome to NICE Technology Appraisals Appraisals in Progress ECT - Electroconvulsive Therapy 8 April 2003
E-newsletter
About NICE
TechnologyAppraisals
Clinical Guidelines
Interventionalprocedures
Clinical Audit
Board Meetings
NationalCollaborating Centres
Citizens Council
Publications
Press Office
Conference
Job Vacancies
Links
News Archive
Using this Site
English
Cymraeg
Vision Impaired
Email notify
Privacy
ECT - Electroconvulsive TherapyTitle The clinical effectiveness and cost effectiveness of electroconvulsive
Therapy (ECT) for depressive illness schizophrenia catatonia andmania
Scope Consultation on a draft scope took place in October 2001
Appraisal Status In progressExpected Date of Issue April 2003 Project team Technology AppraisalProject Manager
Kathleen Dalby E-mail enquiries kdnicenhsuk
Executive Lead Professor Peter LittlejohnsTechnical Lead Dr Sarah GarnerCommunications Manager Lucy Betterton E-mail enquiries LucyBettertonnicenhsuk ScheduleClosing date for invited comments on Scope 15 October 2001Information Meeting for consultees 17 January 2002Closing date for invited submissions 25 February 2002First Appraisal Committee Meeting 26 June 2002Second Appraisal Committee Meeting 24 July 2002Third Appraisal Committee Meeting 22 October 2002 Review GroupSchool of Health and Related Research University of Sheffield
Invited Stakeholders
Association of Anaesthetists of Great Britain and Ireland
Association of British Health-Care Industries
British Psychological Society
Dantec Dynamics Ltd
Department of Health
Depression Alliance
ECT Anonymous
Ectron Ltd
Health Technology Board for Scotland
Isle of Wight Portsmouth and South East Hampshire Health Authority
Long Term Medical Conditions Alliance
Manic Depression Fellowship
Mental Health Act Commission
MIND
MIND Cymru
National Schizophrenia Fellowship
Royal College of Anaethetists
Royal College of Nursing
Royal College of Psychiatrists
SANE
ECT - Electroconvulsive Therapy - NICE
httpwwwniceorgukcataspc=20218 (1 of 3) [842003 094627]
SEARCH NICE
Advancedraquo
Welcome to NICE Technology Appraisals Appraisals in Progress Bi-polar disorder - new drugs 8 April 2003
E-newsletter
About NICE
TechnologyAppraisals
Clinical Guidelines
Interventionalprocedures
Clinical Audit
Board Meetings
NationalCollaborating Centres
Citizens Council
Publications
Press Office
Conference
Job Vacancies
Links
News Archive
Using this Site
English
Cymraeg
Vision Impaired
Email notify
Privacy
Bi-polar disorder - new drugsTitle The clinical effectiveness and cost effectiveness of new drugs for
bi-polar disorder This page contains information on key dates contacts and consultees for the above appraisal Asdocuments relating to this appraisal eg the Scope press releases Appraisal ConsultationDocument and Final Appraisal Determination are produced they will be published on the websiteLinks to these documents can be found at the bottom of the page As this page is updated a shorthistory will be created in the Project History section below Scope Consultation on a draft scope took place in May 2002
Status In progressExpected Date of Issue July 2003 Project team Technology AppraisalsProject Manager
Kathleen Dalby E-mail enquiries kdnicenhsuk
Executive Lead Andrea SutcliffeTechnical Lead Dr Sarah GarnerCommunications Manager Lucy Betterton Email enquiries LucyBettertonnicenhsuk ScheduleClosing date for invited comments on draftscope
30 May 2002
Final scope published June 2002Information Meeting for consultees 15 August 2002Closing date for invited submissions 21 October 2002First Appraisal Committee Meeting 25 February 2003Second Appraisal Committee Meeting 24 April 2003 Review GroupNHS Centre for Reviews and Dissemination University of York
Invited ConsulteesAstraZeneca
British Association for Psychopharmacology
Cambridge City PCT
Department of Health
Eli Lilly
Health Technology Board for Scotland
Institute of Psychiatry
Long Term Medical Conditions Alliance
Manic Depression Fellowship
Marceacute Society
Mental After Care Association
Mental Health Foundation
Mentality
MIND
MIND Cymru
National Collaborating Centre for Mental Health
Bi-polar disorder - new drugs - NICE
httpwwwniceorgukcataspc=19915 (1 of 2) [842003 094723]
SEARCH NICE
Advancedraquo
Welcome to NICE Clinical Guidelines Guidelines and cancer service guidance in progress Eating disorders 18 April 2003
E-newsletter
About NICE
TechnologyAppraisals
Clinical Guidelines
Interventionalprocedures
Clinical Audit
Board Meetings
NationalCollaborating Centres
Citizens Council
Publications
Press Office
Conference
Job Vacancies
Links
News Archive
Using this Site
English
Cymraeg
Vision Impaired
Email notify
Privacy
Eating disordersFull title Eating disorders the management of anorexia nervosa bulimia nervosa and binge eating disorders
The full scope for this Guideline can be found at the bottom of the page when finalised
Status In progressExpected date of issue January 2004
Lead Collaborating Centre The National Collaborating Centre for MentalHealth
Contact person Catherine Pettinari
Email Catherinepettinarivirginnet
NICE project team Guidelines Coordinator Elaine Paton
Email enquiries eatingdisordersnicenhsuk
Guidelines Commissioning Manager Christine Sealey
Executive Lead Andrea Sutcliffe
Communications Manager Phil Ranson
Email enquiries PhilipRansonnicenhsuk
Provisional schedule Consultation on draft scope bystakeholders
May-June 2001
Meeting with patientcarerstakeholder organisations
July 2001
Final scope posted on website November 2001 First Guideline Development Groupmeeting
March 2002
Submission of evidence bystakeholders
May 2002
Consultation on first draft ofguideline by stakeholders
June 2003
Consultation on final draft ofguideline
August 2003
Expected date of issue January 2004
Guideline Development GroupThe Guideline Development Group (GDG) oversees the development process
Stakeholders
Eating disorders - NICE
httpwwwniceorgukcataspc=20079 (1 of 3) [1842003 165738]
SEARCH NICE
Advancedraquo
Welcome to NICE Clinical Guidelines Guidelines and cancer service guidance in progress Self Harm 18 April 2003
E-newsletter
About NICE
TechnologyAppraisals
Clinical Guidelines
Interventionalprocedures
Clinical Audit
Board Meetings
NationalCollaborating Centres
Citizens Council
Publications
Press Office
Conference
Job Vacancies
Links
News Archive
Using this Site
English
Cymraeg
Vision Impaired
Email notify
Privacy
Self HarmFull title Self harm the short-term physical and psychological management and secondary preventionof self harm in primary and secondary care
The full scope for this Guideline can be found at the bottom of the page when finalised
Status In ProgressExpected date of issue March 2004
Lead Collaborating Centre The National Collaborating Centre for MentalHealth is leading this work
Contact person Rebecca King
Email rebeccakingvirginnet
NICE project team
Guidelines Coordinator Elaine Paton
Email enquiries selfharmnicenhsuk
Guidelines Commissioning Manager Christine Sealey
Executive Lead Andrea Sutcliffe
Communications Manager Lucy Betterton
Email enquiries LucyBettertonnicenhsuk
Provisional schedule Consultation on draft scope bystakeholders
8 February - 8 March 2002
Meeting with patientcarerstakeholder organisations
March 2002
Final scope posted on website May 2002 First Guideline Development Groupmeeting
May 2002
Submission of evidence bystakeholders
TBC
Consultation on first draft ofguideline by stakeholders
September 2003
Consultation on final draft ofguideline
November 2003
Expected date of issue March 2004
Guideline Development GroupThe Guideline Development Group (GDG) oversees the development process
Stakeholders
Self Harm - NICE
httpwwwniceorgukcataspc=20115 (1 of 3) [1842003 165802]
SEARCH NICE
Advancedraquo
Welcome to NICE Clinical Guidelines Guidelines and cancer service guidance in progress Obsessive compulsive disorder (OCD) 18 April 2003
E-newsletter
About NICE
TechnologyAppraisals
Clinical Guidelines
Interventionalprocedures
Clinical Audit
Board Meetings
NationalCollaborating Centres
Citizens Council
Publications
Press Office
Conference
Job Vacancies
Links
News Archive
Using this Site
English
Cymraeg
Vision Impaired
Email notify
Privacy
Obsessive compulsive disorder (OCD)Full title Anxiety Management of obsessive compulsive disorder in adults in primary secondary andcommunity care
The full scope for this Guideline can be found at the bottom of the page when finalised
Status NewExpected date of issue February 2005
Lead Collaborating Centre The National Collaborating Centre for MentalHealth
Contact person Catherine Pettinari
Email catherinepettinarivirginnet
NICE project team Guidelines Coordinator Elaine Paton
Email enquiries ocdptsdnicenhsuk
Guidelines Commissioning Manager Chirstine Sealey
Executive Lead Andrew Dillon
Communications Manager Lucy Betterton
Email enquiries LucyBettertonnicenhsuk
Provisional schedule Consultation on draft anxiety scopeby stakeholders
27 November ndash 3 January 2002
Meeting with patientcarerstakeholder organisations
4 March 2002
Final scope posted on website February 2003 First Guideline Development Groupmeeting
March 2003
Submission of evidence bystakeholders
TBC
Consultation on first draft ofguideline by stakeholders
July 2004
Consultation on final draft ofguideline
October 2004
Expected date of issue February 2005
The Editorial BoardThe Guideline Development Group (GDG) oversees the development process
Obsessive compulsive disorder (OCD) - NICE
httpwwwniceorgukcataspc=33922 (1 of 3) [1842003 165845]
SEARCH NICE
Advancedraquo
Welcome to NICE Clinical Guidelines Guidelines and cancer service guidance in progress Post-traumatic Stress Disorder (PTSD) 18 April 2003
E-newsletter
About NICE
TechnologyAppraisals
Clinical Guidelines
Interventionalprocedures
Clinical Audit
Board Meetings
NationalCollaborating Centres
Citizens Council
Publications
Press Office
Conference
Job Vacancies
Links
News Archive
Using this Site
English
Cymraeg
Vision Impaired
Email notify
Privacy
Post-traumatic Stress Disorder (PTSD)Full title Anxiety Management of post-traumatic stress disorder in adults in primary secondary andcommunity care
The full scope for this Guideline can be found at the bottom of the page when finalised
Status In ProgressExpected date of issue January 2005
Lead Collaborating Centre The National Collaborating Centre for MentalHealth
Contact person Rebecca King
Email rebeccakingvirginnet
NICE project team Guidelines Coordinator Elaine Paton
Email enquiries ocdptsdnicenhsuk
Guidelines Commissioning Manager Christine Sealey
Executive Lead Andrew Dillon
Communications Manager Lucy Betterton
Email enquiries LucyBettertonnicenhsuk
Provisional schedule Consultation on draft anxiety scopeby stakeholders
27 November - January 2002
Meeting with patientcarerstakeholder organisations
4 March 2002
Final scope posted on website April 2003 First Guideline Development Groupmeeting
February 2003
Submission of evidence bystakeholders
FebruaryMarch 2003
Consultation on first draft ofguideline by stakeholders
June 2004
Consultation on final draft ofguideline
August 2004
Expected date of issue January 2005
Guideline Development Group (GDG)The Guideline Development Group (GDG) oversees the development process
Post-traumatic Stress Disorder (PTSD) - NICE
httpwwwniceorgukcataspc=57890 (1 of 3) [1842003 165915]
SEARCH NICE
Advancedraquo
Welcome to NICE Clinical Guidelines Guidelines and cancer service guidance in progress Depression in children 18 April 2003
E-newsletter
About NICE
TechnologyAppraisals
Clinical Guidelines
Interventionalprocedures
Clinical Audit
Board Meetings
NationalCollaborating Centres
Citizens Council
Publications
Press Office
Conference
Job Vacancies
Links
News Archive
Using this Site
English
Cymraeg
Vision Impaired
Email notify
Privacy
Depression in childrenFull title Depression in children identification and management of depression in children and young peoplein primary care and specialist services
The full scope for this Guideline can be found at the bottom of the page when finalised
Status In progressExpected date of issue March 2005
Lead Collaborating Centre The National Collaborating Centre for MentalHealth
Contact person Michelle Clark
Email michelleclarkuclacuk
NICE project team
Guidelines Coordinator Elaine Paton
Email enquiries depressioninchildrennicenhsuk
Guidelines Commissioning Manager Chris Sealey
Executive Lead Andrew Dillon
Communications Manager Lucy Betterton
Email enquiries LucyBettertonnicenhsuk
Provisional schedule Consultation on draft scope bystakeholders
28th November - 9th January 2003
Meeting with patientcarerstakeholder organisations
10th December 2002
Final scope posted on website February 2003 First Guideline Development Groupmeeting
February 2003
Submission of evidence bystakeholders
TBC
Consultation on first draft ofguideline by stakeholders
August 2004
Consultation on final draft ofguideline
December - January 2004
Expected date of issue March 2005
Guideline Development GroupThe Guideline Development Group (GDG) oversees the development process
Stakeholders
Depression in children - NICE
httpwwwniceorgukcataspc=33920 (1 of 3) [1842003 165934]
SEARCH NICE
Advancedraquo
Welcome to NICE Clinical Guidelines Completed guidelines and cancer service guidance Schizophrenia core interventions in the treatment and management of schizophrenia in primary and secondary care18 April 2003
E-newsletter
About NICE
TechnologyAppraisals
Clinical Guidelines
Interventionalprocedures
Clinical Audit
Board Meetings
NationalCollaborating Centres
Citizens Council
Publications
Press Office
Conference
Job Vacancies
Links
News Archive
Using this Site
English
Cymraeg
Vision Impaired
Email notify
Privacy
Schizophrenia core interventions in the treatmentand management of schizophrenia in primary andsecondary care
The National Institute for Clinical Excellence has issued its first fully commissioned clinical guideline on theappropriate treatment and care of individuals with schizophrenia within the NHS in England and WalesNICE clinical guidelines ensure that no matter where people live in England and Wales they can beconfident that the health professionals caring for them are working to high-quality evidence based nationalstandards
2003008 NICE welcomes full schizophrenia guideline and training programme
25 March 2003
The National Institute for Clinical Excellence (NICE or the Institute) has today (25 March 2003)welcomed the publication of the full schizophrenia guideline by the National Collaborating Centre forMental Health (NCCMH)
In addition the Institute supports the launch of a new training package that will enable healthcareprofessionals to familiarise themselves with the schizophrenia guideline in an interactive trainingprogramme
Schizophrenia guideline training website
25 March 2003
The National Collaborating Centre for Mental Health has developed a training website for healthprofessionals that gives information on how to understand and use the NICE schizophrenia guidelinewhat the guideline is and how it was developed and the basic concepts underlying the evidence-basedguideline
Click on the link above to access the website (please note this will take you to the Royal College ofPsychiatrists website)
2002062 First clinical guideline from NICE sets out recommendations for NHS care in schizophrenia
4 December 2002
The National Institute for Clinical Excellence has issued its first fully commissioned clinical guidelineon the appropriate treatment and care of individuals with schizophrenia within the NHS in England andWales NICE clinical guidelines ensure that no matter where people live in England and Wales they canbe confident that the health professionals caring for them are working to high-quality evidence basednational standards
Media Briefing - Clinical guideline on Schizophrenia
4 December 2002
Schizophrenia core interventions in the treatment and management of schizophrenia in primary andsecondary care (NICE guideline)
4 December 2002
This is the NICE guideline that has been issued as guidance to the NHS in England and Wales
Schizophrenia core interventions in the treatment and management of schizophrenia in primary and secondary care - NICE
httpwwwniceorgukcataspc=42424 (1 of 2) [1842003 170336]
SEARCH NICE
Advancedraquo
Welcome to NICE Technology Appraisals Appraisals in Progress 8 April 2003
E-newsletter
About NICE
TechnologyAppraisals
Clinical Guidelines
Interventionalprocedures
Clinical Audit
Board Meetings
NationalCollaborating Centres
Citizens Council
Publications
Press Office
Conference
Job Vacancies
Links
News Archive
Using this Site
English
Cymraeg
Vision Impaired
Email notify
Privacy
Appraisals in ProgressAll the technology appraisals currently in development are listed below Click on a title to go to a summarysheet showing key dates the project history contact details and a list of the consultees for the appraisal
The list can be sorted by title (alphabetically) wave number or anticipated publication date - simply clickon the relevant column heading in the blue box once or twice depending on whether you want an ascendingor descending list For more information on using the list and the terms and abbreviations click here
Title Wave AnticipatedPublication
Date
Alzheimers disease - memantine (Ebixa) 8 TBC
Asthma (uncontrolled) - Omalizumab (Xolair) 8 TBC
Atopic dermatitis (eczema) - Pimecrolimus (Elidel) and tacrolimus(Protopic)
8 TBC
Atopic dermatitis (eczema) - topical steroids 8 TBC
Bi-polar disorder - new drugs 6 July 2003
Breast cancer (early) - hormonal treatments 8 TBC
Breast Cancer - capecitabine 6 May 2003
Colorectal cancer - capecitabine and tegafur uracil 6 May 2003
Conduct disorder parent training programmes for treatment andprevention
8 TBC
Coronary events - statins 8 TBC
Coronary Imaging - myocardial perfusion scintigraphy in the diagnosis andmanagement of cardiac disease
7 November 2003
Dementia (non-Alzheimer) - New pharmaceutical treatments 8 TBC
Diabetes (Type 2) - Glitazones (review) R April 2003
Diabetes - patient education models 6 May 2003
Diabetic foot ulcers - new treatments 8 TBC
Dual chamber pacing 8 TBC
Dyspepsia - Proton pump inhibitors (PPIs) (review) R May 2004
ECT - Electroconvulsive Therapy 6 April 2003
Epilepsy in adults - newer drugs 6 October 2003
Epilepsy in children - newer drugs 6 October 2003
Flu - (prophylaxis) amantadine and oseltamivir 6 October 2003
Gastro-intestinal stromal tumours - imatinib (Glivec) 8 TBC
Heart disease - drug eluting stents for the prevention of restenosis andreview of coronary artery stents
7 August 2003
Hepatitis C - pegylated interferons ribavarin and alfa interferon 7 November 2003
Appraisals in Progress - NICE
httpwwwniceorgukcatta2aspc=17935 (1 of 2) [842003 094526]
Vinnulagbull Vinna sem er thornverfagleg og kerfisbundinbull Unnieth aacute oacutehaacuteethann haacutett eetha iacute thornaeth minnsta thornannig
aeth hagsmunatengsl seacuteu ljoacutes ndash minnkar liacutekur aacute skekkju (ldquobiasrdquo)
bull Heimildarvinna seacute skyacuterbull Vinnan aacute aeth vera gagnsaelig
ndash Sjaacute SIGN ldquomethodologyrdquo aacute vef landlaeligknis
Aeth byggja aacute bestu upplyacutesingum
bull Getur leitt tilbull Gagnsaeligrri aacutekvoumlrethunartoumlkubull Aukinnar aacutebyrgethar
ndash roumlkstuethningur fyrir aacutekvoumlrethunum verethur aethgengilegur
bull Mats aacute oacutevissu ndash ljoacutest er hve soumlnnun er mikil eetha liacutetil
bull Notkun viacutesindaniethurstaethna aacute kostnaeth reynslu og hyggjuvits
Hvers vegna leiethbeiningar
bull THORNaeth er engin launung aacute thornviacute aeth KL er ma aeligtlaeth aeth takmarka kliacuteniacuteskt frelsi aeth aacutekveethnu marki
bull Iacute heilbrigethiskerfi sem rekieth er fyrir almannafeacute aacute ekki aeth lyacuteethast aeth veitt seacute laeligknisthornjoacutenusta sem hefur oacutesannaeth gildi er oacuteoumlrugg og hugsanlega haeligttuleg eetha er oacutehoacuteflega kostnaetharsoumlm
bull Council of Europe
Evidence Based Informatics
bull Forsendur betri heilsu iacute gegnum EBI
ndash Stjoacuternendur veretha aeth aeth geta greint aacute milli goacuteethra og leacutelegra upplyacutesinga
ndash Breytt thornekking thornarf aeth leietha til breytinga iacute framkvaeligmd heilbrigethisthornjoacutenustu
ndash Breytt thornjoacutenusta thornarf aeth leietha til betri uacutetkomu fyrir skjoacutelstaeligethinga okkar
httpagathayorkacukwelcomehtm
HTA - Guidelines
- LL index KL
- vinnuhoacutepar
- CIOP
- DM II
- x Ray
- ACS endurliacutefgun
- anaphylax
- COPD
- aethrir vefir
-
- laeligknablaeth
- nice appraisals index
- SIGN
- SIGN depr
- SIGN BTS asthma
- SIGN hip fract
- SBU dvt
- NZGG card rehab
-
- CPG HTA
- KM onc index
- suzuki
- methodology
- levels of evidence
- COCHRANE DEPRESSION ANXIETY AND NEUROSIS GROUP abstracts
- About The Cochrane Library
-
- valproate bipolar
- Cochrane kava anxiety
-
- nofreelunchorg
- NICE
-
- nice guide
-
- wisdom
- vinnulag
- why CPG
- HTA leit
- NICEpdf
-
- MHHGPEDHMCEOGCHHPPCFKEIELDOCICCH
-
- form1
-
- x
-
- f9 Go
- f8
- f7 simple
- f6 153
-
- f10
-
- PKIJPAHBPPENKBNEOAICCBIIFDOKDCBI
-
- form1
-
- x
-
- f1 ssserver_siteini
- f2
- f3 GO
-
- f4
-
- IGMGENAMDKPMBENMAEJNFOHDPEGNGBFG
-
- form1
-
- x
-
- f1 Leitaroreth
-
- f2
-
- JBJFMPKJOPDLABJNHCEBMEGBDHICCPMN
-
- form1
-
- x
-
- f9 Go
- f8
- f7 simple
- f6 17935
-
- f10
-
- OFADFMFMFCODECCIHGPMBBLIKBGPBADCIA
-
- form1
-
- x
-
- f9 Go
- f8
- f7 simple
- f6 20218
-
- f10
-
- JCHDPJMDHGCGFCDNJAEODOONGAGBMDGH
-
- form1
-
- x
-
- f9 Go
- f8
- f7 simple
- f6 19915
-
- f10
-
- HJKMCGGJMJAKBPEANIBMNJJMGPEBPIEJ
-
- form1
-
- x
-
- f6 20079
- f7 simple
- f8
- f9 Go
-
- f10
-
- IJLIKNEOJGNDFEHOAEOHOLDIPHKGHOAL
-
- form1
-
- x
-
- f6 20115
- f7 simple
- f8
- f9 Go
-
- f10
-
- MMFMDAOMFMFMIKJKOAKNAPBEJPLLNKMPNGJG
-
- form1
-
- x
-
- f6 33922
- f7 simple
- f8
- f9 Go
-
- f10
-
- MOFIFLCCAGJJKGPCBAIDOPDNKBKOJOPL
-
- form1
-
- x
-
- f6 57890
- f7 simple
- f8
- f9 Go
-
- f10
-
- DKEOBCBKAFOMGFFHPNBGFIAPBOIHOBBO
-
- form1
-
- x
-
- f6 33920
- f7 simple
- f8
- f9 Go
-
- f10
-
- LJDCEPADAFGNCBOFIDHHLGPPJIAOJAMM
-
- form1
-
- x
-
- f6 42424
- f7 simple
- f8
- f9 Go
-
- f10
-
- KIJLNKLOPNHGEIIBDCOBOCDLPNILKJME
-
- form1
-
- x
-
- f1 Leitaroreth
-
- f2
-
- JANJPBIEFCNALOHNABEGNPNGKDAKFOHO
-
- form1
-
- x
-
- f1 Leitaroreth
-
- f2
-
- NKNBMKKEECAJAIIPGDMCJCGBGIBGOEND
-
- form2
-
- x
-
- f1 [Hraethval]
-
- form3
-
- x